Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
2-11-2021 1:00 PM

Characterizing the Anxiolytic Potential and Synergistic Efficacy of
Cannabidiol and d-limonene
Nathashi Jayawardena, The University of Western Ontario
Supervisor: Laviolette, Steven, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Neuroscience
© Nathashi Jayawardena 2021

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Alternative and Complementary Medicine Commons

Recommended Citation
Jayawardena, Nathashi, "Characterizing the Anxiolytic Potential and Synergistic Efficacy of Cannabidiol
and d-limonene" (2021). Electronic Thesis and Dissertation Repository. 7654.
https://ir.lib.uwo.ca/etd/7654

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
Emerging evidence has elucidated the anxiolytic properties of the cannabis-derived
phytochemicals cannabidiol (CBD) and d-limonene and the ‘Entourage Effect’
wherein, multiple components of cannabis synergize to produce stronger effects than
their pure counterparts. However, no studies have yet explored this effect in
combinations of CBD and limonene. Thus, the present thesis investigated the
anxiolytic and synergistic potential of concurrently administered intra-nucleus
accumbens shell CBD (1 ng/0.5 µl or 5 ng/0.5 µl) and inhaled limonene (200 µl or
2000 µl). Additionally, the role of the 5-HT1A receptor in mediating these effects was
examined by co-application of the antagonist NAD299 and by the assessment of
downstream molecular biomarkers. Findings from this study demonstrated for the first
time that relative to their isolated counterparts, combinations of limonene and CBD
more effectively reduces symptoms of anxiety, with the observed reversal of these
effects with NAD299 elucidating a role at the 5-HT1A receptor.
Keywords:
Cannabis, Cannabidiol, CBD, d-limonene, limonene, cannabinoid, monoterpene,
terpene, Entourage Effect, anxiety, 5-HT1A, NAD299, nucleus accumbens shell,
mesocorticolimbic system.
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Summary for Lay Audience
Current medications for anxiety disorders are fraught with adverse side-effects
such as ongoing drug dependence, withdrawal, and memory loss. Thus, there is a
critical need for the development of novel pharmacotherapies with safer and more
tolerable profiles. While cannabis use has been associated with an increased risk of
psychosis, these effects are associated with the cannabinoid tetrahydrocannabinol
(THC). In contrast, extensive evidence has demonstrated that the cannabis-derived
phytochemicals, cannabidiol (CBD) and d-limonene, possess anxiolytic properties,
with several studies associating the anti-anxiety effects of CBD with specific brain
regions associated with reward and mood dysfunction, namely the nucleus accumbens
shell (NASh).
The citrus-scented monoterpene, d-limonene, has been shown to reduce
anxiety in pre-clinical and clinical assays in a similar biochemical manner to CBD. In
addition to their analogous properties, emerging evidence has alluded to a
phenomenon known as the ‘Entourage Effect’ (EE). The Entourage Effect posits that
multiple components in the cannabis plant interact to produce a stronger influence
than each component in isolation, i.e., a synergistic effect. This effect is documented
mainly for THC and other cannabis-derived phytochemicals and there is currently no
knowledge of how combinations of CBD and limonene may produce clinically
synergistic effects. Thus, this research project examined dose combinations of coapplied intra-NASh CBD and inhaled d-limonene that may provide the greatest
anxiolytic efficacy, as well as assess associated changes in protein expression in the
brain by pre-clinical modeling of anxiety-related behavioural and molecular assays in
rodents.
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The results of this study demonstrate for the first time the EE-potentiated
anxiolytic effects of concurrently administered CBD and d-limonene. Additionally, by
utilizing a specific molecular antagonist (NAD299) and by assessing changes in
anxiety-related biomarkers, this thesis elucidated the potential 5-HT1A receptormediated signalling brain pathways targeted by these formulations. Ultimately, these
findings combined with the evidence that CBD and limonene exhibit remarkably safe
pharmacological profiles, highlight the therapeutic potential of cannabis-derived
compounds and their prospective use as a natural alternative or adjunct to current antianxiety medications.
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1. Introduction
1.1 Properties of Cannabis sativa
Cannabis sativa, also referred to as marijuana or simply as cannabis, is the
most popular drug consumed with approximately 147 million people using it
worldwide (WHO|Cannabis, n.d.). This figure equates to 2.5% of the global
population – higher than the prevalence rate of 0.2% for cocaine and 0.2% for opiates
(WHO|Cannabis, n.d.). With the legalization of marijuana in several American states
and federally in Canada in October 2018, there has been growing concern with
regards to how recreational or medicinal use can impact human health. While
evidence suggests that cannabis consumption can have detrimental effects on
learning, memory, and motor function, several other studies have alluded to the
potential therapeutic benefits of various cannabis constituents (Niesink & van Laar,
2013; Renard et al., 2017; Volkow et al., 2014). This heterogeneity of cannabisinduced psychological effects reflects the complex molecular interactions between its
various phytochemicals and their biological substrates.
The cannabis plant contains over 500 phytochemicals of which 104 have been
identified as cannabinoids (components that interact specifically with the cannabinoid
(CB) receptors of the brain) (Pertwee, 2014). Two of these cannabinoids, Δ9tetrahydrocannabinol (Δ9-THC or THC) and cannabidiol (CBD), have garnered
particular scientific interest due to their relatively high concentrations in the plant and
their distinctive psychological effects. Ingestion of THC, the main psychoactive
component of cannabis, has been shown to lead to impairments in learning and
memory, with chronic exposure resulting in psychosis and schizophrenia (Lafaye,
2017; Renard et al., 2017). In contrast, evidence suggests that CBD may have a
neuroprotective effect, potentially antagonizing the negative consequences of THC
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(Niesink & van Laar, 2013). Specifically, pre-clinical and clinical assays have alluded
to the ability of CBD to alleviate symptoms of stress, anxiety, and depression (Crippa
et al., 2018; Millar et al., 2019). For instance, a study by Crippa and colleagues (2011)
found that oral administration of cannabidiol resulted in a significant reduction in
subjective levels of anxiety in individuals with social anxiety disorder (SAD), with
subsequent changes in activity in the limbic and paralimbic systems of the brain.
In addition to cannabinoids, the aromatic compounds known as terpenes, have
been shown to possess psychoactive properties (Russo, 2011). Terpenes (organic
hydrocarbons) are most abundantly found in essential oils and to varying degrees in
different strains of cannabis. Over 200 of the 20,000 terpenes described have been
identified in cannabis with the most common being limonene, β-myrcene, α-pinene,
linalool, and β-caryophyllene (Russo, 2011). While terpenes constitute less than 1%
of most cannabis assays, concentrations as low as 0.05% have been deemed to be
pharmacologically significant (Başer & Buchbauer, 2016; Russo, 2011). Moreover,
emerging preclinical evidence has alluded to the potential anticonvulsant,
antidepressant, and anxiolytic effects of specific monoterpenes (Carvalho-Freitas &
Costa, 2002; Elisabetsky et al., 1995; Komiya et al., 2006). For instance, inhalation of
limonene by mice results in a reduction in anxiety-related behaviour (Lima et al.,
2013). While several reports demonstrate the potential clinical significance of
terpenes, studies characterizing their pharmacological profile remain scarce.
In addition to the isolated effects of cannabis-derived compounds, various
accounts demonstrate synergistic efficacy between these substances (Russo, 2011).
The phenomenon, dubbed the ‘Entourage Effect’, suggests that multiple components
within cannabis may interact, thereby producing a stronger influence on the body than
each component in isolation. For example, Carlini et al. (1974) found that
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administration of crude cannabis extracts produced effects two to four times greater
on pulse rate and psychological disturbance than their pure THC counterparts. Such
findings alluding to cannabis synergism are of particular interest for the development
of therapeutic agents for various mental health disorders. Specifically, the
demonstrated anxiolytic effects of certain terpenes, such as limonene, and the
phytocannabinoid, CBD, combined with the rationale of the Entourage Effect, suggest
that specific terpene-phytocannabinoid formulations may work together to more
effectively reduce symptoms of anxiety. Consequently, we utilized a rodent model to
examine whether specific combinations of CBD and the monoterpene, d-limonene,
could more effectively alleviate anxiety-related behaviours. Moreover, we sought to
characterize the associated molecular changes in the brain induced by these drug
formulations.
1.2 Overview of Anxiety
1.2.1 Defining Anxiety and Anxiety Disorders
The feeling of anxiety is often composed of three parts: 1) worried thoughts,
2) specific bodily sensations, such as increased heart rate or respiration, and 3)
particular actions, such as running away or freezing (Craske & Stein, 2016). Anxiety
is a normal reaction to potentially threatening or stressful life events and healthy
individuals manage their anxiety by employing adaptive coping mechanisms. These
strategies are often divided into two categories: emotion-based behaviours wherein,
the individual seeks to regulate their emotions that arise as a consequence of the
stressor, or problem-based behaviours that directly resolve the stressor (Biggs et al.,
2017). Occasionally, however, anxiety may persist in the absence of an external
stressor, or symptoms may be unusually severe or frequent. When symptoms of
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anxiety begin to interfere with one or more activities of daily living, the individual
may be diagnosed with an anxiety disorder.
The nine types of anxiety disorders characterized by the American Psychiatric
Association in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
(DSM-V) are generalized anxiety disorder (GAD), social anxiety disorder (SAD) or
social phobia, separation anxiety disorder, selective mutism, specific phobias, panic
disorder, agoraphobia, substance/medication-induced anxiety disorder, and anxiety
disorder due to another medical condition, such as post-traumatic stress disorder
(PTSD). For many individuals diagnosed with one or more of these conditions,
management of anxiety requires therapeutic intervention in the form of psychotherapy
and/or medication.
1.2.2 Prevalence of Anxiety Disorders
Anxiety disorders are the most prevalent type of neuropsychiatric illness. In
2017, the proportion of the global population with an anxiety disorder was estimated
to be 3.8% (equivalent to 284 million people) – higher than depression (3.4%),
alcohol abuse (1.4%), and eating disorders (0.2%) (Global Burden of Disease, 2017).
Moreover, the lifetime prevalence of having an anxiety disorder, based on large
population-based surveys was 33.7%, with estimates of rates as high as 70% in people
with chronic health conditions (Bandelow & Michaelis, 2015; Remes et al., 2016).
While these findings signify the already high occurrence of the disease, more recent
evidence suggests that these figures can increase during socioeconomic and political
upheavals. During the COVID-19 pandemic of 2020, several studies reported an
increase in anxiety amongst the general population, with one meta-analysis reporting
a proportion as high as 31.9% in a sample of 63,439 individuals (Luo et al., 2020;
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Salari et al., 2020). Not surprisingly, economic uncertainty influences population
mental health.
Anxiety disorders are highly treatable and when left untreated have significant
personal and societal costs such as frequent medical visits, decreased work
productivity, unemployment, and impaired social relationships (Simpson et al., 2010).
Moreover, untreated anxiety is a risk factor for the development of other anxiety and
mood disorders, as well as substance abuse (Remes et al., 2016), consequently,
making treatment more difficult and contributing to low remission rates, poor
prognosis, and risk of suicide (Nutt et al., 2007; Simpson et al., 2010). Given the
pervasiveness of the illness and the associated consequences when left untreated, it is
imperative that effective treatment exists for those struggling with an anxiety
disorder.
1.2.3 Current Treatment for Anxiety
Treatment for anxiety is broadly categorized into two types: psychotherapy
and anti-anxiety medication. Psychotherapy-based interventions include cognitivebehavioural therapy (CBT), psychodynamic therapy, and behavioural therapy. CBT is
the most widely utilized of the psychotherapies and is highly effective for various
types of anxiety disorders (Hoffman & Smits, 2008). However, a recent meta-analysis
by van Dis and colleagues (2020) suggests that CBT’s efficacy may be short-lived for
some forms of anxiety. Over 69 randomized clinical trials including 4118 patients,
skills and insights acquired through CBT were maintained 12-months post-treatment
but failed to result in improved outcomes after 12-months for panic disorder (with or
without agoraphobia) (van Dis et al., 2020). Given the chronic nature of anxietyrelated disorders, the long-term efficacy of therapeutic intervention is critical for
successfully managing the illness.
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In addition to psychotherapy, anxiety is frequently treated using
pharmacotherapeutic agents. First-line anxiolytics include benzodiazepines, selective
serotonin reuptake inhibitors (SSRIs), and serotonin and norepinephrine reuptake
inhibitors (SNRIs), which modulate GABAergic, serotonergic, and serotonergic and
norepinephrine brain pathways, respectively. In comparison to CBT, these drugs
demonstrate similar treatment efficacy in terms of long-term symptom management
and relapse rates, while being more convenient than recurrent weekly sessions of
psychotherapy (Bandelow et al., 2018). Regardless of their remedial effects, however,
anxiolytic drugs are associated with considerable side-effects, dependence, and when
terminated, severe symptoms of withdrawal (Bandelow et al., 2018; Mackinnon &
Parker, 1982; Owen & Tyrer, 1983).
A review by Ravindran and Stein (2010) found that SSRI usage frequently
resulted in symptoms of nausea, dizziness, jitteriness, sleep difficulties, and
gastrointestinal disturbances – akin to the symptoms associated with anxiety. Due to
the severity of these adverse reactions, patients often terminated their treatment
prematurely before the medication had enough time to reach maximum efficacy
(Ravindran & Stein, 2010). These findings were further corroborated by a more recent
study, wherein, 318 children and adolescents reported their adherence to
antidepressants for anxiety 3-12 years after initial treatment (Kagan et al., 2020).
Researchers found that 40.6% of the 318 patients discontinued their medication with
reports of primary concerns of perceived ineffectiveness (31.8%) and side-effects
(25.5%) (Kagan et al., 2020). When side-effects are managed and treatment can be
continued long-term, these drugs can lead to cognitive impairments and increased risk
of developing dementia (Barker et al., 2004; Chan et al., 2017; Ravindran & Stein,
2010). Moreover, when drug doses are reduced or terminated, associated symptoms of
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withdrawal include, perceptual disturbances, epileptic seizures, weight loss, insomnia,
and autonomic symptoms, often leading to the reliance on higher drug doses (Owen &
Tyrer, 1983).
In summary, while current interventions can be successful in relieving anxiety
they are replete with short and long-term problems. Thus, there is an urgent need for
the development of safer, novel pharmacotherapies that not only possess fewer sideeffects and better long-term outcomes, but also encourage patient adherence which is
critical for the treatment of chronic anxiety.
1.3 Serotonergic (5-HT) System and Anxiety
Multiple treatment studies, genetic research, and neuroimaging data have
implicated dysregulated serotoninergic (5-HTergic) neurotransmission as a primary
contributor in mood and anxiety disorders (Durant et al., 2010; Jans et al., 2007;
Ravindran & Stein, 2010). That said, the existing literature is contradictory on
whether anxiety is provoked in states of 5-HT excess or deficiency (Albert et al.,
2014; Durant et al., 2010). Some assays employing 5-HT agonists report anxiogenic
symptoms (Charney et al., 1987), while others demonstrate anxiolysis (Crippa et al.,
2011). This discrepancy is a result of the differential binding of these agonists to
specific 5-HT receptors (5-HTR). For example, the anxiogenic agent utilized by
Charney et al. (1987), m-chlorophenylpiperazine (m-CPP), is a 5-HT1CR agonist,
while the anti-anxiety agent employed by Crippa et al. (2011), cannabidiol, is a wellestablished 5-HT1AR agonist. Thus, the 5-HT receptor subtype modulated by potential
therapeutic agents for anxiety is an important aspect to consider.
5-HT receptors are broadly categorized into five families based on their
mechanism of action: 5-HT1, 5-HT2, 5-HT3, 5-HT5, and the family of 5-HT4, 5-HT6,
and 5-HT7 (Siegel, 1999). Within these families, receptors may be further subdivided
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into A, B, C, D, E, and F subtypes (such as 5-HT1A, 5-HT1D, 5-HT2A, etc.) (Siegel,
1999). Among them, the 5-HT1A receptor in particular has been implicated in the
etiology of anxiety disorders.
Specifically, 5-HT1A heteroreceptors are reduced in patients with social
anxiety disorder, and in the cortical regions of patients with panic disorder
(Lanzenberger et al., 2007; Neumeister et al., 2004). Additionally, homozygous and
heterozygous 5-HT1AR knockout (KO) mice display significantly increased levels of
anxiety, indicating that a partial receptor deficit is sufficient to elicit the phenotype
(Akimova et al., 2009). Generally, extensive evidence suggests that alterations in 5HT1AR expression is common in several affective and anxiety-related disorders,
suggesting that it may be a general marker of psychopathology.
1.3.1 Mechanism of Action of 5-HT1A Receptors
5-HT1AR is a major inhibitory G-protein coupled receptor (GPCR) subtype
that exerts its effects through Gi/Go proteins, thereby, modulating several intracellular
signalling pathways such as, adenylyl cyclase (specifically inhibition) (Barnes &
Sharp, 1999), mitogen-activated protein kinases (MAPK), and Akt (Polter & Li,
2010). 5-HT1A receptors are classified into two populations within the central nervous
system (CNS): autoreceptors and heteroreceptors.
5-HT1A autoreceptors can be found on the soma and dendrites of the 5-HT
producing neurons in the dorsal and median raphe nuclei (DRN and MRN,
respectively) of the brainstem, where their activity results in hyperpolarization and
reduced firing of the cell (Hjorth & Sharp, 1991; Verge et al., 1985). Thus, activation
of these autoreceptors creates a negative feedback loop that decreases the release of
extracellular 5-HT into projection areas (Hjorth & Sharp, 1991; Verge et al., 1985)
(Figure 1).
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5-HT1A heteroreceptors innervated by 5-HTergic neurons are expressed on
postsynaptic excitatory pyramidal neurons (Azmitia et al., 1996; Palchaudhuri &
Flügge, 2005) and GABAergic interneurons (Santana et al., 2004) mainly in the
prefrontal cortex (PFC) and regions of the limbic system such as the hippocampus
(HP), nucleus accumbens (NAc), and amygdala (AMG) (Azmitia & Segal, 1978;
Beck et al., 1992; Li et al., 2006; Pompeiano et al., 1992). Similar to 5-HT1A
autoreceptors, stimulation of heteroreceptors results in nerve cell hyperpolarization
(Dong et al., 1998; Sprouse & Aghajanian, 1988). Common anxiolytics, such as
SSRIs and SNRIs, work by preventing the re-uptake of released 5-HT, enabling
activation of postsynaptic 5-HT1A heteroreceptors (Palchaudhuri & Flügge, 2005;
Santana et al., 2004). Thus, hyperpolarization of target neurons leads to the
subsequent reduction of fear and anxiety-related symptoms (Palchaudhuri & Flügge,
2005; Santana et al., 2004).

Figure 1: Depiction of a Serotonergic (5-HT) Neuron Negative Feedback via 5HT1A Autoreceptors. 5-HT1A activation inhibits neuronal firing and 5-HT release.
Blue squares represent 5-HT1A receptors; Red circles are 5-HT.
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1.4 The Mesocorticolimbic (MCL) Pathway
The mesocorticolimbic system, often referred to as the ‘reward pathway’,
represents the brain’s major dopaminergic (DA) system and has been implicated in
numerous mood and anxiety disorders (Alex & Pehek, 2007). Subdivided into the
mesocortical and mesolimbic pathways, they both contain dopaminergic (A10)
neurons that originate primarily from the ventral tegmental area (VTA) located in the
midbrain (Alex & Pehek, 2007) (Figure 2). The mesocortical pathway projects to the
prefrontal cortex (PFC), which regulates complex cognitive processes (Alex & Pehek,
2007). Conversely, the mesolimbic pathway projects to the nucleus accumbens (NAc)
and olfactory tubercle (referred together as the ventral striatum of the basal ganglia),
mediating endogenous and exogenous drug-induced reward responses (Ekhtiari &
Paulus, 2016; Robbins & Everitt, 1996; Schultz, 2016); this path is also associated
with complex circuits involving the amygdala, hippocampus, and the bed nucleus of
the stria terminalis (BNST), which modulate emotion, memory, and
autonomic/neuroendocrine/behavioral responses, respectively (Ekhtiari & Paulus,
2016). Notably, the MCL pathway receives prominent serotonergic innervations from
the MRN and DRN and thus, 5-HT1AR agonists have been shown to modulate 5-HT
release and DA neuronal activity within the MCL system (Chen & Reith, 2002).
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Figure 2: Depiction of the Mesocorticolimbic (MCL) System Differentiating the
Cortico and Limbic Pathways. Dopaminergic projections are represented in blue;
Serotonergic projections from the raphe nuclei to the VTA, VST, PFC, and AMG are
shown in red.
1.4.1 Nucleus Accumbens (NAc)
The nucleus accumbens consists of two anatomical components: the core
(NAcc) and the shell (NAcSh/NASh). The main output neurons of both divisions are
the medium spiny neurons (MSN) – a special type of GABAergic inhibitory cell
containing multiple dopamine receptors (Salgado & Kaplitt, 2015). The activity of
these efferent projections is modulated by glutamatergic afferents arising from the
prefrontal cortex, hippocampus, and amygdala, by dopaminergic afferents from the
ventral tegmental area, by serotonergic afferents from the raphe nucleus, and by
noradrenergic afferents from the locus coeruleus (Shirayama & Chaki, 2006).
The NAc is central in modulating social motivation (i.e., the need to obtain
social rewards and avoid social punishment) – a behaviour often disrupted in
mood/anxiety disorders (American Psychiatric Association, 2013). Utilizing eventrelated functional magnetic resonance imaging (fMRI), Kohls et al. (2013) observed
that the anticipation of social reward (i.e., approval) and the anticipation of avoidable
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social punishment (i.e., disapproval) resulted in the activation of the nucleus
accumbens. Additionally, an fMRI study conducted by Levita et al. (2012) found that
the NAc was associated with active and passive avoidance. Specifically, the NAc
displayed increased activation during active avoidance (i.e., pressing of a button that
stopped the presentation of an aversive image), and increased deactivation during
passive avoidance (i.e., withholding a button press that prevented the aversive image
from appearing); critically, the degree of these activity patterns was correlated with
individual levels of anxiety (Levita et al., 2012).
Given the extensive evidence associating the nucleus accumbens with anxious
phenotypes, the NAc has garnered research interest as a stereotaxic target for
therapeutic agents. For instance, the application of three different antipsychotic drugs
has been shown to increase Fos expression (a marker of metabolically active neurons)
within the NASh, highlighting its role as a site of antipsychotic action (Deutch et al.,
1992). Moreover, a study by Norris et al. (2016) alluded to the therapeutic effects of
intra-NASh cannabidiol in ameliorating anxiety-related behaviour. Specifically,
microinfusions of CBD blocked the formation of fear-related memory (via 5-HT1A
receptor activation) (for more details see Properties and Mechanisms of Action of
Cannabidiol). Consequently, CBD within the NASh represents a potential remedy in
alleviating behaviours associated with anxiety.
1.4.2 Functional Associations between the NAc, VTA, PFC, and BLA
Nucleus Accumbens and Ventral Tegmental Area (NAc-VTA)
The NAc-VTA circuit has been implicated in various anxiety-related
behaviours such as aversion (Danjo et al., 2014) and social dysfunction (van der Kooij
et al., 2018). While the VTA sends dopaminergic projections to the NAc (Han et al.,
2017), the NAc in turn reciprocally modulates VTA DAergic and non-DAergic
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neuronal activity via MSN GABAergic efferents (Kalivas et al., 1993; Nauta et al.,
1978; Norris et al., 2016)(Figure 3). Notably, this NAc

VTA connection is

modulated via 5-HT1AR signalling and regulates fear-related behaviour associated
with pre-clinical assays of anxiety (Norris et al., 2016) (for a detailed description see
Properties and Mechanisms of Action of Cannabidiol). Consequently, these effects of
the NAc on the VTA indirectly alter the activity of the PFC via the mesocortical
pathway (Alex & Pehek, 2007), and equally, PFC

VTA connectivity modulates

NAc dopamine release (Karreman & Moghaddam, 2002).
Nucleus Accumbens and Prefrontal Cortex (NAc-PFC)
In addition to indirect regulation, the PFC executes top-down control of the
NAc via direct glutamatergic excitatory input (Brady, 2004; Sesack & Pickel, 1992)
and GABAergic input (Lee et al., 2014; Torregrossa et al., 2008)(Figure 3).
Dysfunction within the PFC-NAc circuitry is associated with abnormal cognitive
behaviours observed in schizophrenia (Meyer-Lindenberg et al., 2002; Pantelis,
1997), and glutamatergic PFC

NAc projections have been linked to drug-seeking

behaviours (Bossert et al., 2012; Park et al., 2002). Furthermore, the PFC

NAc

GABAergic transmission is shown to provoke real-time avoidance behaviour upon
optogenetic stimulation, suggesting that this path transmits aversive signals (Lee et
al., 2014), having implications for disorders such as agoraphobia and panic disorder.
Basolateral Amygdala (BLA)
Evidence suggests that the amygdala is functionally connected to the MCL
circuitry (Nazari-Serenjeh & Rezayof, 2013; Reznikov et al., 2018). The two
subregions of the human amygdala include: 1) the basolateral amygdala (BLA) and 2)
the cortico-medial amygdala; the cortico-medial amygdala is linked to agonistic
behaviour related to fear and the basolateral amygdala is known for encoding the
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threat value of a stimulus (Etkin et al., 2004; Luiten et al., 1985; Mai et al., 2016).
Notably, the BLA-VTA mutually interact to form memories associated with
avoidance learning (Nazari-Serenjeh & Rezayof, 2013) and conditioned fear (de
Oliveira et al., 2011), and similarly, deep brain stimulation within the PFC attenuates
fear and anxiety-related symptoms by reducing BLA firing in pre-clinical assays of
PTSD (Reznikov et al., 2018). It should be noted that while extensive literature has
alluded to the top-down regulation of PFC-BLA relations, the BLA in turn project
glutamatergically to the PFC, modulating emotional responses within this circuit
(Cheriyan et al., 2016; McGarry & Carter, 2016). Finally, the BLA-NAc circuit
suppresses punished reward-seeking responses, and thus, dysfunction within this path
is proposed to have implications for compulsive behaviours related to OCD
(Piantadosi et al., 2017).
In summary, these findings illustrate the integrative and systematic nature in
which the NAc, VTA, PFC, and BLA function, and the distinctive and analogous
effects they have on anxiety-related behaviours. Critically, this physiological
connectivity and interactive affective processing highlight the importance of
considering collective neural activity in the development of pharmacological agents
that are specific and minimally disruptive to the functioning of associated brain
regions.
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Figure 3: Functional Connections between the MCL System and Associated
Brain Regions. Arrow legend: Blue = Dopaminergic, Red = GABAergic, Yellow =
Glutamatergic, Grey = Serotoninergic.

1.4.3 Targeting the MCL System in the Treatment of Anxiety
Given the robust evidence demonstrating the role of the mesocorticolimbic
system in emotion and cognition from pre-clinical assays of anxiety, this system is
frequently a region of interest in clinical interventions. Sturm et al. (2003)
demonstrated that the application of deep brain stimulation (DBS) to the NASh in
patients with severe anxiety and OCD (who were unresponsive to psycho- and
pharmacotherapy) was correlated with a significant reduction in anxiety symptoms.
These results were corroborated by a subsequent study by Denys and colleagues
(2010) validating the effective use of intra-NAc DBS in patients with OCD. Aside
from being a focus for therapy, the NAc represents a potential biomarker for
predicting treatment outcomes as greater pre-treatment NAc volume is linked to a
greater reduction in anxiety symptoms upon treatment with CBT and SSRIs
(Burkhouse et al., 2020). Moreover, similar changes in structural volume have been
demonstrated in the PFC, with decreased PFC volumes positively correlating with
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worry scores in persons with generalized anxiety disorder (GAD) (Mohlman et al.,
2009).
As a chief component of the cortical limb of the MCL pathway and with its
top-down inhibition of the amygdala, the PFC plays a significant role in modulating
cognitive states and fear-responses related to anxiety. While adolescents with GAD
display increased activation of the PFC in response to angry faces relative to control
subjects, increased PFC activation is associated with less severe anxiety, implying
that it may serve a compensatory role by enabling those with GAD to regulate their
responses to anxiety-provoking stimuli, possibly through the PFC’s functional
connections with the amygdala (Monk et al., 2006). This assertion is supported by
Ironside et al. (2019) whereby, transcranial direct current stimulation (tDCS) of the
PFC in subjects with high trait anxiety increased attentional control, while
simultaneously reducing amygdala threat reactivity.
The activity of the principal dopaminergic input of the MCL system, the
ventral tegmental area, is likewise connected to clinical anxiety. Patients with GAD
display heightened VTA-mesocorticolimbic coupling and attenuated VTAhippocampal coupling in response to generalized stimuli during fear generalization
tasks (Cha et al., 2014) supporting the contention that the treatment of anxiety
necessitates the consideration of related brain regions at the systems-level as opposed
to isolated structures. As a note, the long-term memory consolidating structure, the
hippocampus, possesses circuit-level interactions with the VTA, NAc, and PFC
(Godsil et al., 2013; Kahn & Shohamy, 2013) with dysfunctional associations having
implications for the onset of anxiety symptoms (Marusak et al., 2017). Finally,
pharmacological targeting of the VTA with specific natural medicines has been
shown to ameliorate symptoms of GAD potentially via VTA dopaminergic
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associations within the MCL system (Herrera-Arellano et al., 2012; Prieto-Gómez et
al., 2003).
1.5 Receptor Targets and Downstream Molecular Signalling of Anxiety
As mentioned previously, atypical serotonergic conduction specifically with
regards to 5-HT1AR is associated with the onset, maintenance, and treatment of
anxious phenotypes (see Serotonergic (5-HT) System and Anxiety). Additionally,
increasing data have revealed the anxiogenic effects of reduced GABA transmission
(Goddard et al., 2001), specifically as it pertains to key brain structures of the MCL
system. Reduced GABA levels within the PFC and GABAR antagonists within the
VTA have been observed to increase anxiety (Frye & Paris, 2009; Ghosal et al.,
2017), and in a similar vein, the injection of GABAR agonists into the NASh is linked
to anxiolytic behaviours (Lopes et al., 2012). Notably, the functional connections
between the NAc and VTA (specifically, the GABAergic NAc

VTA projections)

signify that GABA alterations in one region can have implications for the other
(Norris et al., 2016). Ultimately, these studies highlight the importance of inhibitory
control within the MCL system in modulating anxiety and the clinical relevance of
GABA receptors, as exhibited by the conventional anxiolytic benzodiazepine.
Both 5-HTR and GABAR are associated with anxiety-related downstream
signalling pathways with notable protein biomarkers being: ERK, JNK, Akt, and
GSK3 (Ailing et al., 2008; Crofton et al., 2017; Hollos et al., 2018; Matsuda et al.,
2019) (Figure 4). While the activity of these proteins results in phenotypically similar
anxiety-associated symptoms, their effects on downstream targets exhibit distinctive
mechanisms of action.
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1.5.1 ERK
The extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2,
respectively) are members of the mitogen-activated protein kinase (MAPK)
superfamily of signalling cascades that mediate cellular processes such as
proliferation, differentiation, and apoptosis (Mebratu & Tesfaigzi, 2009). In addition
to their physiological effects, phosphorylated ERK (p-ERK) within the PFC is linked
to high levels of anxiety (Ailing et al., 2008), and inhibited 5-HT1AR has been found
to increase activation of the ERK pathway (via increased p-ERK) within the
hippocampi of PTSD mice thereby, increasing anxiety symptoms (Xiang et al., 2017).
Moreover, compounds in cannabis are able to modulate this cascade. In particular,
intra-hippocampal infusions of THC increases salience attribution in fear conditioning
assays, which are reversed upon the co-application of CBD due to the downregulation
of p-ERK1/2; additionally, pharmacological reactivation of pERK1/2 blocks these
behavioural effects by CBD (Hudson et al., 2019). Thus, the antipsychotic effects of
cannabidiol appear to be modulated by the ERK1/2 pathway, specifically within the
context of brain regions associated with the MCL system.
1.5.2 JNK
Also, members of the MAPK family, c-Jun N-terminal kinases 1, 2, and 3
(JNK1, JNK2, and JNK3, respectively) are involved in cellular processes and
activated by stressful stimuli similar to ERK proteins (Johnson & Nakamura, 2007).
Consequently, given that oxidative stress can induce anxiety and depression (Hassan
et al., 2014), it is unsurprising that the JNK1 isoform has been implicated in these
mood disorders (Hollos et al., 2018). Specifically, JNK1 knockout mice display
increased hippocampal neurogenesis and subsequent alleviation of anxiety and
depression, with JNK inhibition being sufficient in yielding these effects (Mohammad
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et al., 2018). Thus, JNK has been causally implicated in the neurogenesis hypothesis
of anxiety, which postulates that the generation of new neurons within the
hippocampus throughout adulthood suppresses anxious behaviour (Revest et al.,
2009). Furthermore, while 5-HT1AR-mediated ERK phosphorylation leads to the
initiation of anti-apoptotic pathways, 5-HT1AR stimulation of JNK in the same cell
line results in pro-apoptosis, suggesting that the ultimate consequence of 5-HT1AR
activity on MAPK proteins is dependent on their respective role within the tissue
(Masson et al., 2012).
1.5.3 Akt
Protein kinase b (Akt) is a member of the PI3K-Akt signal transduction
pathway, which is activated by the phosphorylation of its serine-473 and threonine308 residues; this phosphorylates downstream targets, including the protein glycogen
synthase kinase 3 (GSK3), involved in cell survival and growth (Manning & Cantley,
2007). Notably, this phosphorylation is related to 5-HT homeostasis, as mice with
inhibited phosphorylation of Akt (p-Akt) at Ser473 display elevated cortical
expression of 5-HT1AR (Saunders et al., 2014). Moreover, the isoform Akt2 is
involved in mood stabilization and fear memory with Akt knockout mice displaying
significantly increased anxiety in pre-clinical behavioral assays such as the light-dark
box and open field test (Leibrock et al., 2013). Finally, varying genotypes of the Akt2
gene have been associated with human personality traits related to anxiety and
depression, highlighting its pharmacological significance in treating mood disorders
(Engeli et al., 2014).
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1.5.4 GSK3
Glycogen synthase kinase 3 (GSK3) is a serine/threonine protein kinase
primarily phosphorylated and inactivated by Akt as a downstream target of the PI3KAkt pathway (Cross et al., 1995). Existing as two isoforms, GSK3α and GSK3β, it
participates in cell signalling and transport, as well as in the etiology of mood
disorders (Jope, 2011). In mice, silencing GSK3β within the NASh decreases the
intrinsic excitability of tonically active interneurons (TANs), consequently leading to
a reduction in anxiety-like behaviour (Crofton et al., 2017). Indeed, several studies
have validated that GSK3β modulates behaviours linked to aberrant 5-HT
transmission and that 5-HT1AR agonists increase phosphorylated GSK3β within the
cerebral cortex, hippocampus, and striatum (Latapy et al., 2012; Polter & Li, 2010).
Finally, several classes of 5-HT modulating drugs, such as SSRIs, exert their actions
by inhibiting GSK3, reinforcing the significance of targeting this protein in
neuropsychiatric disease (Polter & Li, 2011).
It should be noted that the aforementioned proteins, of which anxiety-related
modulatory roles are mentioned in isolation, work in a concerted manner through
direct and indirect interactions with each other. Consequently, their ultimate
behavioural outcomes, based on activation or inactivation, is dependent on the brain
region targeted, as well as the complex interplay between these molecules.
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Figure 4: 5-HT1A Receptor-Mediated Downstream Molecular Targets. Proteins
discussed in this thesis are highlighted. Jun/Fos, CREB, and FoxO represent
transcription factors. JNK = c-Jun N-terminal kinase, ERK = extracellular signalregulated kinase, Akt = protein kinase b, GSK = glycogen synthase kinase.
1.6 The Endocannabinoid System and Mental Health
Despite thousands of years of cannabis use for recreational and medicinal
purposes, interest in cannabinoid receptor pharmacology did not begin until the
isolation of THC and the discovery of its psychoactive properties in 1964 (Maroon &
Bost, 2018; Russo, 2011). Subsequent research in the early 1990s unveiled the
specific membrane receptors of THC, thus leading to the identification of the
endogenous signalling system – the endocannabinoid system (ECS) (Maroon & Bost,
2018). Consequently, the endogenous cannabinoids (cannabis-like substances)
derived from arachidonic acid, N-arachidonoylethanolamine (anandamide; AEA) and
2-arachidonoylglycerol (2-AG) were identified (Maroon & Bost, 2018).
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The two major endogenous cannabinoid receptors of the ECS system are the
CB1 and CB2 G protein-coupled receptors (Pertwee, 2008). Binding of
phytocannabinoids and endogenous cannabinoids to these receptors within the
mammalian brain has been found to modulate effects on emotion, motor control, and
cognition (Rodrigues de Fonseca et al., 2005). Additionally, within the central and
peripheral nervous systems, they play a crucial role in regulating the autonomic
nervous system, immunity, and microcirculation (Rodrigues de Fonseca et al., 2005).
Notably, the antagonistic effects of CBD and THC are owing to their
differential receptor binding. While THC is a partial agonist at the CB1 and CB2
receptors, CBD acts as a negative allosteric modulator of the CB1 receptor and a weak
indirect antagonist of the CB2 receptor (Pertwee, 2008). Critically, by targeting these
receptors, their exogenous and endogenous ligands, and endocannabinoid degradative
enzymes, recent pharmacological advances have successfully manipulated the ECS
system to treat pain, neurological disease, and psychiatric and emotional disorders,
like anxiety and drug addiction (Maroon & Bost, 2018).
1.6.1 Cannabis-Derived Treatment
While there is evidence of cannabis-derived treatment dating back to 2700
B.C. and reports of pharmaceutical use in the 19th century, their definitive induction
into Western medicine is a more recent phenomenon (Zuardi, 2006). The first
cannabis-derived medication, Sativex, was approved and launched in the United
Kingdom on June 21st, 2010, with 29 other countries, including Canada, following
suit shortly after; this 1:1 THC-CBD oral spray is used for the treatment of pain and
spasticity caused by multiple sclerosis (Freeman et al., 2019). On June 25th, 2018, the
US Food and Drug Administration (FDA) approved Epidiolex, an oral CBD solution,
for the treatment of seizures associated with two severe forms of childhood epilepsy –
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Lennox-Gastaut syndrome and Dravet syndrome (Mead, 2019). Additionally, some
countries, including the US, Netherlands, and Germany, have now licensed the use of
two synthetic-THC products, Dronabinol and Nabilone, both of which serve as a
weight loss treatment for patients with AIDS and an anti-emetic for patients receiving
chemotherapy (Freeman et al., 2019). Although whole-plant extracts have yet to be
approved by the FDA, growing evidence of the therapeutic effects of cannabis has
prompted the World Health Organization to propose that cannabis should be
rescheduled for medical use within international law (Mayor, 2019). Specifically, in
the case of CBD, its excellent safety profile and tolerance even at high doses have
highlighted its clinical value in treating mood and anxiety disorders (Taylor et al.,
2018).
1.6.2 Properties and Mechanisms of Action of the Phytocannabinoid Cannabidiol
Cannabidiol (CBD) comprises about 40% of most Cannabis sativa extracts,
making it the second most abundant component after THC (Grlic, 1976). CBD
interacts with a host of different receptors; critically, its anxiolytic effects have been
associated with the vanilloid receptor TRPV1 (Iannotti et al., 2014), the serotonin
receptor 5-HT1A (Norris et al., 2016), and the endocannabinoid receptor CB1
(Pertwee, 2008).
Activation of the TRPV1 channel is linked to the etiology of psychiatric
disorders such as anxiety and fear-associated responses (Chahl, 2011). For instance,
compared to wild-type mice, TRPV1 knockout mice display less anxiety-related
symptoms as measured by the light-dark box test, the elevated plus maze, and the fear
conditioning paradigm (Marsch et al., 2007; Santos et al., 2008). Moreover, CBD has
been shown to dose-dependently activate and subsequently desensitize TRPV1
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channels (Iannotti et al., 2014); thus, the reported anxiolytic effects of CBD may be
related to its direct interactions with this receptor.
Conversely, evidence suggests that CBD may modulate these effects indirectly
through the endocannabinoid anandamide (AEA). AEA is an agonist at the TRPV1
channel (Ross, 2003) and the CB1 receptor (of which CBD is not a primary ligand)
(Dasilva et al., 2014). Studies demonstrate that CBD increases levels of AEA by
inhibiting its hydrolytic enzyme, fatty acid amide hydrolase (FAAH) (Leweke et al.,
2012), and by inhibiting AEA uptake via its presumed AEA transporter (Bisogno et
al., 2001). Since increased AEA is negatively associated with psychotic symptoms,
the antipsychotic effects of CBD have been attributed to its effects on AEA levels.
Notably, the administration of CBD in patients with acute schizophrenia results in the
reduction of psychotic symptoms comparable to the potent antipsychotic drug
amisulpride, while bearing less negative side-effects (Leweke et al., 2012).
While the exact biochemical interactions of CBD are still debated, extensive
behavioural and molecular assays have robustly linked it as an agonist at the 5-HT1A
receptor (de Gregorio et al., 2019; Norris et al., 2016; Resstel et al., 2009; Russo et
al., 2005). The study by Norris et al. (2016) (mentioned earlier under Nucleus
Accumbens) demonstrating that intra-NASh CBD can block the formation of
conditioned freezing behaviors, unveiled a novel circuit between the NASh and the
ventral tegmental area via NASh 5-HT1AR transmission. Specifically, CBD decreased
DAergic neuronal activity in the VTA, while simultaneously increasing VTA
GABAergic neuronal activity, with the reversal of these neuronal effects and
restoration of associative fear memory formation upon administration of NAD299 (a
5-HT1AR antagonist) (Norris et al., 2016).
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Furthermore, the ability for CBD to facilitate GABAergic activity and
modulate anxiety has been associated with its interactions with the GABA receptor
subtype, GABAA, while exhibiting no interactions at GABABR (Bakas et al., 2017;
Straiker et al., 2018). Specifically, CBD acts as a positive allosteric modulator at the
GABAA receptor (Bakas et al., 2017; Onaivi et al., 1990), which is similar to the
actions of the anxiolytic drug, benzodiazepine (Roy-Byrne, 2005). Given that GABAA
activation inhibits GABA interneurons within the ventral striatum and subsequently
increases NAc firing (Mallet, 2005), CBD may possess a GABAAR-NAc-mediated
route in inhibiting VTA dopaminergic transmission within the MCL system, thereby,
modulating anxiety symptoms.
In addition to its reported regulation of multiple anxiety-related receptor
targets, oral ingestion of CBD demonstrates an excellent safety profile with adverse
reactions being mild or moderate in severity after two daily doses of 1500 mg (Taylor
et al., 2018). Notably, a single oral dose of 400 mg of CBD is enough to significantly
decrease subjective levels of anxiety in patients with GAD (Crippa et al., 2011), while
a 600 mg dose is effectual in patients with SAD (Bergamaschi et al., 2011).
Consequently, given its relatively superior tolerability and effective modulation of 5HT and GABA, CBD represents an excellent candidate as an alternative or
supplementary agent to conventional anxiolytics.
1.6.3 Properties and Mechanisms of Action of the Monoterpene Limonene
For centuries, essential oils have been utilized for the treatment of infection,
inflammation, and mood disorders (Ali et al., 2015). In particular, there are extensive
reports from traditional and folk medicine on the anxiolytic effects of Citrus essential
oils (such as that found in Citrus aurantium L.) with the emergence of more recent
empirical evidence supporting its therapeutic use in pre-clinical and clinical settings
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(Lehrner et al., 2000; Leite et al., 2008; Lima et al., 2013; Rombolà et al., 2017). For
instance, numerous rodent in-vivo studies have demonstrated that lemon essential oil
can reduce levels of stress, anxiety, and depression (d’Alessio et al., 2014; de
Almeida et al., 2012; Komiya et al., 2006; Lima et al., 2013). In humans, drops of
lemon essential oil scattered in a dental office lobby were shown to reduce anxiety of
awaiting patients (Lehrner et al., 2000), while oral administration reduced
preoperative anxiety levels of patients scheduled for minor elective surgery (Akhlaghi
et al., 2011).
The anxiolytic effects of essential oils are largely attributed to the aromatic
compounds known as terpenes. The major chemical component (constituting up to
96.24%) of Citrus essential oil is the monoterpene hydrocarbon limonene (Leite et al.,
2008); in cannabis extracts, limonene represents 16% of the fresh bud oil (Ross &
ElSohly, 1996). Moreover, emerging pre-clinical data has alluded to the
pharmacologically similar effects of limonene and cannabidiol and their analogous
modulation of activity within the MCL system.
Komiya et al. (2006) reported that inhalation of lemon essential oil by mice
decreased measures of anxiety in the pre-clinical assay, the elevated plus maze
(EPM). Moreover, pre-treatment with the anxiolytic buspirone (a 5-HT1A agonist) and
the antipsychotic haloperidol (a D2, D3, D4 antagonist) potentiated the anxiolytic
effects of inhaled lemon oil, while flumazenil (a GABAAR antagonist) blocked these
effects (Komiya et al., 2006). Considered together these findings provide support for
the assertion that lemon oil modulates DAergic activity via interactions with the 5HTnergic and/or GABA receptor complex (Komiya et al., 2006). One possible
mechanism of action is that components of lemon oil, such as limonene, activate
raphe nuclei serotonergic transmission to the VTA and associated regions of the MCL
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system, which subsequently suppresses DAergic neuronal activity (Komiya et al.,
2006). These results of limonene regulation of the 5-HT, dopamine, and GABA
systems are corroborated by other studies (Fukumoto et al., 2006; Lima et al., 2013;
Yun, 2014; Zhou et al., 2009) with one study by Yun (2014) demonstrating limoneneassociated reversal of methamphetamine-induced dopamine release specifically in the
nucleus accumbens.
Furthermore, in addition to its reported effects on stress and mood, limonene
represents an attractive candidate in drug therapy due to its potential non-invasive,
olfactory administration and low toxicity. The LD50 values for d-limonene in male
and female rats (in g/kg body weight), respectively, are 4.4 and 5.1 (oral), 3.6 and 4.5
(intraperitoneal), > 20 and > 20 (subcutaneous), and 0.12 and 0.11 (intravenous),
categorizing limonene as ‘practically non-toxic’ according to the Hodge and Sterner
toxicity scale (Tsuji et al., 1975). While extrapolation of these doses to humans
should be conducted with caution, evidence from a Phase I clinical trial suggests that
limonene toxicity, upon oral administration, is limited to gastrointestinal symptoms
(such as irritation, nausea, and diarrhea), and are associated with exceptionally high
doses in the range of 6.5–12 g/m2 body surface area per day (Vigushin et al., 1998).
Given its relatively safe pharmacological profile and described anxiolytic
efficacy, limonene represents an appealing alternative to current anxiolytic
pharmacotherapies. This is further supported by its reported interactions with wellestablished anxiety-related targets, such as 5-HT1AR (Costa et al., 2013). Moreover,
the similar mechanistic profile that limonene shares with CBD makes it a suitable codrug for the examination of synergistic efficacy as it relates to the Entourage Effect.

28
1.7 Synergy and the Entourage Effect (EE)
Synergy is the enhanced potency of combined pharmacological agents that is
greater than their presumed additive effects (Greco et al., 1996). These co-operative
interactions often allow for the use of lower doses of each drug, thereby, reducing the
likelihood for adverse reactions. In line with this synergism principle, the Entourage
Effect refers to the proposed mechanism demonstrating the enhanced psychoactive
potency of combined phytocannabinoid components relative to their isolated
administrations (Ben-Shabat et al., 1998; Russo, 2011). Originally identified amongst
endogenous cannabinoids, recent developments have extended this effect to
exogenous cannabinoids, such as THC and CBD, terpenes, and flavonoids (Ferber et
al., 2020a; Russo, 2011). Critically, studies specifically demonstrating the augmented
therapeutic efficacy of whole-plant or combinatorial extracts of cannabis have
significant implications for the treatment of brain and anxiety disorders.
In an in-vitro rodent model of epilepsy, comparison of a standardized cannabis
extract (SCE) with a matched concentration of pure THC, yielded the SCE as a
stronger and more rapidly-acting anticonvulsant (Wilkinson et al., 2003). Moreover,
Ryan et al. (2006) found that evoked calcium responses within hippocampal neurons
and glia were increased with combinatorial administrations of CBD and THC relative
to pure CBD and THC counterparts and that the response sizes and maximal
responder rates were heightened by CBD-THC mixtures containing additional
phytocannabinoids rather than a pure 1:1 formula of CBD:THC. Consequently, these
findings provide evidence of synergy between THC and CBD, as well as potential
interactions with other cannabis constituents (Ryan et al., 2006).
Four possible mechanisms of synergy have been postulated by Wagner and
Ulrich-Merzenich (2009) which include i) effects at multiple target receptors, ii)
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improved pharmacokinetics such as, enhanced bioavailability, iii) interactions
affecting bacterial resistance, and iv) tempering of adverse events, as in the case of
CBD-inhibition of THC-induced psychotropic effects (Hudson et al., 2019; Niesink &
van Laar, 2013). However, while studies have demonstrated synergistic efficacy
between CBD and THC, as well as within constituents of lemon essential oil (Costa et
al., 2013), there is currently no study that has assessed possible Entourage Effects
between Limonene-CBD formulations (Ferber et al., 2020b). Given the previously
described similarities between CBD and limonene in their modulation of receptor
targets, neuronal communication, and consequent changes in anxiety-associated
behaviours, Limonene-CBD formulations offer a promising avenue in EE-potentiated
treatment of anxiety disorders. Consequently, this thesis examined the potential
synergistic and anxiolytic efficacy of combined sub-threshold doses of LimoneneCBD formulations relative to pure administrations of these phytocannabinoids.
1.8 Hypothesis and Research Aims
General Hypothesis: This study hypothesized that combining sub-threshold
cannabidiol and d-limonene would lead to synergistic efficacy (based on the concept
of the cannabis Entourage Effect, discussed previously), thus, resulting in greater
anxiolytic efficacy in both behavioural and molecular assays compared to the
administration of either compound in isolation.
The following research aims were conducted to test this hypothesis:
Aim 1: Characterize the anxiolytic efficacy of Limonene-CBD formulations relative
to limonene and CBD alone by the administration of compounds through inhalation
and intracranially, respectively, and by subsequent assessment of established rodent
anxiety-related phenotypes in behavioural assays.
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Aim 2: Examine possible 5-HT1A receptor-mediated anxiolysis by co-application of
the antagonist (NAD299) with Limonene-CBD formulations and assess for changes in
behaviour in the same assays conducted in Aim 1.
Aim 3: Determine whether Limonene-CBD formulations alter molecular pathways
associated with anxiety and 5-HT1AR signalling by examining changes in associated
biomarkers (such as ERK1/2 and Akt).
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2. Methods
2.1 Animal Housing
Adult male Sprague Dawley rats (300-400 grams) were housed in pairs upon
arrival from the Charles River Laboratories, Quebec, Canada until surgery. The
following conditions were maintained: 12-hour light/dark cycle, food (rodent chow)
and water ad libitum, and constant temperature and humidity. Cages were plexiglass
rectangular boxes filled with approximately two inches of corn bedding containing
approved objects for environmental enrichment (paper nesting and wood chewing
blocks). Beginning one day after arrival, animals were handled every day for at least
one week to acclimate them to handling procedures. After one week, animals were
ready for surgical cannulation. All experimental procedures were performed in
accordance with the regulations of the Canadian Council on Animal Care (CCAC)
and the University of Western Ontario Animal Care Committee (AUS protocol 2018053). Animals were monitored by both Animal Care and Veterinary Services (ACVS)
and laboratory technicians in the designated animal care facility at Western
University.
2.2 Stereotaxic Surgery
Rats were anesthetized with a 2:1 mixture of ketamine (80 mg/kg; 26
Vetoquinol) and xylazine (6 mg/kg; Bayer) via intraperitoneal injection. Appropriate
anesthetic depth was ensured by the absence of reflexive movement in response to a
toe pinch and lack of whisker twitch in response to light stroking. After confirmation
of anesthesia, subjects were treated with a subcutaneous injection of meloxicam
(1mg/kg) to prevent pain and inflammation; additionally, a second dose was
administered 24-hours post-surgery. Rats were positioned in the stereotaxic apparatus.
Subjects’ body temperature was measured immediately before, during, and after
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surgery and maintained around 36oC - 37oC using a warm heat pad positioned below a
urine pad placed under the rat.
An incision was made to expose the skull and eight-millimeter stainless steel
guide cannulas (22 G; Plastics1) were implanted into the NASh bilaterally using the
following stereotaxic coordinates: 12° angle (mm from bregma): anterior-posterior
(AP) ± 1.8, lateral (LAT) ± 2.6, and ventral (V) – 7.4 from the subject’s dural surface.
All coordinates were based on the Rat Brain Atlas by Paxinos and Watson (2005).
Cannulas were secured to the skull using four miniature screws and dental acrylic
cement. Dust caps were fitted to the cannulas to prevent obstruction by debris.
Following at least one week of recovery, rats were tested in behavioural paradigms.
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2.3 Drug Preparation and Administration
2.3.1. d-limonene
D-limonene (96.9%; MP Biomedicals) was administered through inhalation
according to the following protocol (Harada et al., 2018).
One Day Before Test Day:
To habituate the subjects to the cage where they would receive the odourous
exposure to d-limonene, rats were placed in the cage for 30 minutes one day before
the first test day. In this set-up, subjects were exposed to 200 μL of distilled water.

Figure 5: Schematic of d-limonene Exposure. Left: Top-down view schematic of
plexiglass-cage depicting the position of the four spice jars. Right: Schematic of spice
jar containing a weigh boat at the jar mouth. Weigh boats were filled with limonene
or water depending on treatment designation.

The limonene exposure apparatus was a transparent, rectangular plexiglass
cage with a filter top (which prevented odours from entering or leaving the cage) and
four spice jars in each of the four corners secured to the floor using Velcro adhesive.
Small weigh boats containing distilled water (200 or 2000 μL; V) or d-limonene (200
μL or 2000 μL; L200 or L2K, respectively), were placed on the mouth of each spice
jar. The jars were then secured with lids which contained three holes that allowed the
odours to diffuse into the cage. On test day, rats were exposed to this treatment for 30
minutes just before intracranial CBD infusion.
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Test Day:

Figure 6: Timeline of Drug Administration Prior to Behavioural Test or Brain
Extraction. For brain extractions, animals were administered Euthanyl three minutes
after intracranial CBD infusion and brains were collected immediately after
confirmed euthanasia.
2.3.2 Vehicle, Cannabidiol (CBD), and NAD299 Microinfusions
Vehicle (V) solutions comprised of dimethyl sulfoxide (DMSO; SigmaAldrich), cremophor (Sigma-Aldrich), and 0.9% saline (pH 7.4) in a 1:1:18 ratio.
CBD-only (Tocris) and NAD299 hydrochloride-only (Tocris; 5-HT1AR antagonist)
solutions were created by dissolving the respective drug in DMSO and diluted to their
final concentrations (final DMSO 5% in saline containing 5% cremophor). Target
CBD concentrations were either 1 ng/0.5 μL (CBD(1)) or 5 ng/0.5 μL (CBD(5)) (subthreshold doses; Norris et al., (2016)), while NAD299-only solutions were 100 ng/0.5
μL (effective dose in attenuating CBD anxiolytic effects; Norris et al., (2016)). CBDNAD299 solutions contained 5 ng of CBD and 100 ng of NAD299 in 0.5 μL of
vehicle solution (CBD(5)NAD).
Intracranial microinfusions were administered into the NASh (volume of 0.5
mL per hemisphere) using microinjectors attached to a Hamilton syringe over a 1minute period. Microinjectors were kept in place for an additional one minute
following infusion to ensure that all of the solution had diffused out of the injector tip.
After intracranial infusion, subjects were immediately placed into the designated
behavioural test.
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2.4 Behavioural Assays
2.4.1 Open Field (OF)
The open field test was conducted primarily as a measure of general
locomotor activity, wherein, subjects that displayed significantly abnormal locomotor
activity were excluded from further analysis. The apparatus consisted of a transparent
plexiglass box with approximately two inches of wood chip bedding placed on the
floor for comfort. A grid system of laser interference detection (San Diego
Instruments) assessed various motor movements such as total distance travelled (in
cm) and the total time spent in the center and periphery of the chamber (in seconds).
Rats were placed in this chamber to freely explore for 30 minutes. Data was analyzed
only for the first 5 minutes of the test, however, as most subjects tended to stop
exploration after this time.
2.4.2 Elevated Plus Maze (EPM)
The elevated plus maze task measures open-space anxiety exhibited by rats.
The test apparatus was a black acrylic maze consisting of four arms (10 x 50 cm),
extending from a 10 x 10 cm base platform elevated 50 cm above the floor. The two
‘closed arms’ were shielded with 40 cm high walls, while the two opposing ‘open
arms’ were unshielded except for a 1 cm high ledge which prevented subjects from
falling off the platform during exploration. Relevant measures of this test were: total
time spent in the open arms and the total number of arm transitions. Subjects were
placed diagonally on the center platform facing no particular arm and allowed to
explore the maze for 10 minutes. Exploration behavior was recorded and analyzed
offline (Behaview software; www.pmbogusz.net).
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2.4.3 Three-Chamber Social Interaction (SI)
This test is a measure of the degree of the rodent’s social motivation and
social recognition memory and consists of three-stages (Loureiro et al., 2015). The
test apparatus consisted of three compartments each separated by a removable gate.
One Day Before Test Day:
To acclimate the subjects to the chamber a habituation phase was conducted
one day before test day. The subject was placed in the center compartment with both
gates closed and allowed to explore the center for 5 minutes. After this, the two gates
were opened and the rat was allowed to explore the whole chamber for 8 minutes.
Test Day:
i)

Stage One (S1): Habituation
The next day, the subject was placed in the center compartment for 5 minutes

with both gates closed.
ii)

Stage Two (S2): Social Motivation
After this 5-minute session, an unfamiliar male rat (matched in age and size to

the subject) was placed inside a small wire cage and placed in one compartment,
while a similar empty cage was placed in the other compartment. Both gates were
then lifted and the test subject was allowed to explore both cages for 8 minutes. The
following data was analyzed: time spent sniffing the ‘stranger’ rat and time spent
sniffing the empty cage. Throughout the testing protocol, the placement of the empty
cage and stranger rat were counterbalanced between the left and right compartments
of the test apparatus.
iii)

Stage Three (S3): Social Recognition
Immediately after the second stage, a novel and unfamiliar male rat (matched

in age and size to the subject) was introduced into the empty cage. The test subject
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was allowed to explore both cages for 8 minutes. The following data was analyzed:
time spent sniffing the ‘familiar’ rat (from S2) and time spent sniffing the ‘novel’ rat
(from S3). Subjects’ recorded interaction times with the cages during the task were
analyzed offline (Behaview software; www.pmbogusz.net).
2.4.4 Light-Dark Box (LDB)
The light-dark box test measures bright-space anxiety exhibited by rats, based
on their instinctive tendency to avoid brightly lit environments. The test apparatus
was a non-transparent plexiglass box (50 x 25 x 37 cm) consisting of two equally
sized compartments. The ‘light compartment’ was white, uncovered, and illuminated
by a lamp placed approximately 125 cm above the floor of the compartment. The
‘dark compartment’ was black and lidded. The two compartments were separated by a
10 x 10 cm open doorway, which allowed subjects to easily traverse them.
Subjects were placed in the light compartment with their back facing the open
doorway and observed for a total of 10 minutes. The following data was analyzed:
total time spent in the light, total time spent in the dark, risk assessment (total time
spent by the subject placing its nose or its forepaws into the light compartment from
the dark compartment), as well as the total number of compartmental transitions
during the test session. A transition into a compartment was considered only when all
four feet of the rat was placed in the respective compartment. Test sessions were
recorded and analyzed offline (Behaview software; www.pmbogusz.net).
2.4.5 Contextual Fear Conditioning (CFC)
The contextual fear conditioning paradigm is a test of associative learning and
memory created between an aversive footshock stimulus and a given environment.
While it can be used to measure both memory acquisition and memory recall, this

38
thesis examined memory acquisition only. The test apparatus, adapted from Norris et
al. (2016) consisted of a lidless, tall chamber containing a metallic grid floor
connected to a shocker. The task consisted of two stages conducted over two days.
i)

Stage One: Conditioning Phase
Day 1 of the protocol involved pairing a specific context to an aversive

footshock stimulus. Immediately after subjects received treatment, they were placed
inside a black-and-white striped walled chamber (the context) and administered 10
supra-threshold footshocks. The shock was 0.8 mA, 1 second in duration and, given at
randomized intervals over a 25-minute session.
ii)

Stage Two: Testing Phase
The next day, within 24 hours, rat subjects were placed in this same chamber

and their subsequent freezing behaviour was measured. Recorded data was then
analyzed offline (Behaview software; www.pmbogusz.net)
2.4.6 Experimental Timeline of Behavioural Assays

Figure 7: Testing Timeline of Behavioural Assays (not to scale).
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2.4.7 Experimental Groups in Behavioural Assays
Table 1: Summary of Experimental Cohorts and Treatment Designations Per
Cohort
Research Aim

Aim 1: Characterizing
anxiolysis and
synergy

Aim 2: Examining 5HT1AR modulation

Experimental Cohort

Baseline Cohort
(9 potential groups)

NAD299 Challenge
(8 potential groups)

Treatment Groups
VV, VCBD(1) and/or
VCBD(5), L200V, L2KV,
L200CBD(1) and/or
L200CBD(5), L2KCBD(1)
and/or L2KCBD(5)

VV, VNAD, L200CBD(1)
and/or L200CBD(5),
L2KCBD(1) and/or
L2KCBD(5),
L200CBD(5)NAD,
L2KCBD(5)NAD

2.5 Molecular Analyses
2.5.1. Tissue Extraction
After completion of all behavioural tests, rodent brains were collected for
Western Blot analysis. Prior to euthanasia, rats were subjected to their respective
treatment (odour and drug combination) from behavioural testing. Euthanasia was an
intraperitoneal injection of sodium pentobarbital (EuthanylTM; 240 mg/kg)
administered 3 minutes after intracranial infusion. Animals were decapitated and
extracted brains were frozen at -80oC and sliced within three weeks. To account for
potential minor variations in extracting methods, brains from each cohort of animals
were extracted on the same day.
Using a cryostat, coronal sections (99 μm) of the PFC, NASh, and BLA were
collected and mounted on glass slides. Bilateral tissue samples were extracted from
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these brain regions. NASh microdissections were taken from around the infusion site
to avoid any regions with active gliosis. Tissue samples were homogenized using a
Dounce homogenizer and proteins were then isolated using lysis buffer containing
phosphatase and protease inhibitors. Protein quantification was conducted using the
bicinchoninic acid (BCA) assay.
2.5.2 Western Blots
The Western Blot protocol was adopted from Lyons et al. (2013). Protein
samples were denatured in Laemmli buffer and diluted to ensure an equal
concentration amongst all samples. Each well was loaded with 25 μg of protein
sample and subjected to SDS polyacrylamide gel electrophoresis (SDS-PAGE) at
125V for 1.5 hours in 10% acrylamide gels, followed by transference to nitrocellulose
membranes using the Trans-Blot Turbo Transfer System (Bio-Rad) at 2.5A for 10
minutes. After blocking with 2.5% bovine serum albumin (BSA) in TBS-T for one
hour, membranes were then placed in blocking solution containing the following
primary antibodies with their respective host species and dilutions as follows: αtubulin (mouse; 1:10,000; Sigma-Aldrich), phosphorylated ERK1/2 (p-ERK; rabbit;
1:1000; Cell Signalling Technology), total ERK1/2 (t-ERK; mouse; 1:2000; Cell
Signalling Technology), phosphorylated Akt Ser473 (p-Akt Ser473; rabbit; 1:1000;
Cell Signalling Technology), and total Akt (t-Akt; mouse; 1:1000; Cell Signalling
Technology).
Membranes were subsequently probed with species appropriate fluorophoreconjugated secondary antibodies (LI-COR IRDye 680RD and IRDye 800CW;
Thermo Scientific) at a dilution of 1:10000. LI-COR Odyssey Infrared Imaging
System and Image Studio analysis software were then used to scan and obtain
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densitometry measurements respectively, normalizing the intensity of each sample’s
target protein band to its respective α-tubulin band intensity.
2.6 Histology
Over four cohorts, a total of 145 animals underwent surgery for intra-cranial
cannulation. Following tissue extraction, slides containing the NASh region were
stained using cresyl violet dye as detailed by Loureiro et al. (2015). Stained slides
with visible cannula tips under a confocal microscope were photographed and
assessed for appropriate cannula placement using the Rat Brain Atlas by Paxinos and
Watson (2005). Due to improper cannulation, 11 animals were excluded from analysis
from the following groups: VV [2], VCBD [3], L200V [2], L200CBD [1], and
L2KCBD [3].

A)

B)

Figure 8: Histological Analysis of the Intra-Shell Region of the Mesolimbic
Nucleus Accumbens (NASh) Microinjection Sites. A) Microphotograph of a
representative slide depicting bilateral injector placements within the NASh B) Slide
presented alongside an overlay of the relevant depiction in the Rat Brain Atlas by
Paxinos and Watson (2005). Red arrows point towards the injector tips.
2.7 Statistical Analysis
All statistical analyses were performed using GraphPad Prism (Version 8).
Behavioural and molecular data were analyzed for Gaussian distribution using the
Kolmogorov-Smirnov test. Data was then analyzed using a one-way ANOVA (or
Kruskal-Wallis analysis) or t-test (or Mann-Whitney U-Test). The post-hoc analysis
utilized was Fisher’s LSD. Statistical significance was determined at p < 0.05 and the
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confidence interval was 95%. Statistical outliers were identified using the Grubbs’
Test and removed.
3. Results
3.1 Histology
Histological analysis confirmed injector placements were correctly localized
to the nucleus accumbens shell (NASh) according to the anatomical boundaries
specified in the Atlas by Paxinos and Watson (2005) (Figure 8). Only these animals
were analyzed for further study.
3.2 Baseline Cohort Behavioural Results
3.2.1 Open Field (OF)
The open field test was conducted to assess if treatment groups affected
general locomotor activity. For this test, the number of animals in each group
(excluding histological outliers mentioned in 2.6 Histology) were: VV [9], VCBD(5)
[9], L200V [10], L2KV [12], L200CBD(5) [11], and L2KCBD(5) [9].
General Locomotion
There were no significant differences in the distance travelled between any of
the treatment groups based on a one-way ANOVA analysis (F(5,52) = 0.472, p = .795;
Figure 9B), suggesting that treatment did not affect general locomotion. Thus, the
results from the OF test conclusively eliminated variable locomotor activity as a
confounding variable in all subsequent behavioural assays. Statistical outliers were
identified and removed from the following groups: L200V [1] and L200CBD(5) [1].
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Center Time
The time spent in the center of the chamber was analyzed as a measure of
rodent open-space anxiety. There were no significant differences in the time spent in
the center of the chamber between any of the treatment groups based on the KruskalWallis test (χ2(5) = 5.584, p = .345; Figure 9C). However, there appeared to be a trend
of increasing time spent in the center with increasing volume of limonene and for
Limonene-CBD combination groups. Statistical outliers were identified and removed
from the following group: L2KV [1].
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A) Open Field Schematic

16” x 16”

Figure 9: Open Field (Baseline Cohort). A) A top-down view schematic
of the OF apparatus B) Distance travelled in the first five minutes of the
test. No significant differences were observed between treatment groups;
one-way ANOVA C) Time spent in the center of the apparatus in the first
five minutes of the test. No significant differences were observed between
treatment groups; K-S test. CBD doses were 5 ng/0.5 μL; limonene doses
were 200 μL (L200) or 2000 μL (L2K). Plotted values are the mean ±
SEM; the sample size of each group is represented on the bottom of their
respective bar; p < 0.05.
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3.2.2 Elevated Plus Maze (EPM)
The elevated plus maze test was used to assess rodents’ inherent aversion to
open spaces. Subjects that spend more time in the open arms of the maze are deemed
to be less anxious. Two parameters from this test were analyzed: time in open arms
and the total number of open arm entries. For this test, the number of animals in each
group (excluding histological outliers mentioned in 2.6 Histology) were: VV [9],
VCBD(1) [10], VCBD(5) [10], L200V [8], L2KV [14], L200CBD(1) [8],
L200CBD(5) [13], L2KCBD(1) [8], and L2KCBD(5) [9]. Animals that fell off the
maze and therefore, did not complete the 10-minute assay were excluded from
analysis. These were from: VV [1], VCBD(5) [2], and L200CBD(5) [2].
Time in Open Arms
In comparison to the VV group, L2KV and all Limonene-CBD combination
groups (i.e., L200CBD(1), L200CBD(5), L2KCBD(1), and L2KCBD(5)) spent
significantly more time in the open arms of the maze; p = .041, p = .014, p = .004, p =
.011, and p = .014, respectively. In comparison to the VCBD(1) group, all LimoneneCBD combination groups (i.e., L200CBD(1), L200CBD(5), L2KCBD(1), and
L2KCBD(5)) spent significantly more time in the open arms of the maze; p = .027, p
= .008, p = .021, and p = .028, respectively.
In comparison to the VCBD(5) group, all Limonene-CBD combination groups
(i.e., L200CBD(1), L200CBD(5), L2KCBD(1), and L2KCBD(5)) spent significantly
more time in the open arms of the maze; p = .026, p = .009, p = .020, and p = .026,
respectively.
In comparison to the lowest dose of limonene, L200V, all Limonene-CBD
combination groups (i.e., L200CBD(1), L200CBD(5), L2KCBD(1), and L2KCBD(5))
spent significantly more time in the open arms of the maze; p = .024, p = .008, p =
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.018, and p = .024, respectively. Figure 10B summarizes these findings; one-way
ANOVA analysis (F(8, 75) = 3.173, p = .004).
Total Number of Open Arm Entries
In comparison to the VV group, L2KV and all Limonene-CBD combination
groups except the L200CBD(1) group made significantly more open arm entries.
Individual p values between VV and L2KV, L200CBD(5), L2KCBD(1), and
L2KCBD(5) were p = .026, p = .011, p = .015, and p = .006, respectively.
Compared to the VCBD(1) group, L200CBD(5), L2KCBD(1), and L2KCBD(5)
made significantly more open arm entries; p = .037, p = .047, p = .019, respectively.
Finally, compared to the VCBD(5) group, the L2KCBD(5) group displayed
significantly more open arm entries; p = .039. Figure 10C summarizes these findings;
one-way ANOVA analysis (F(8, 74) = 2.120, p = .044). Statistical outliers were
identified and removed from the following group: L2KV [1].
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A) Elevated Plus Maze Schematic

Figure 10: Elevated Plus Maze (Baseline Cohort). A) A top-down view schematic of the EPM
apparatus B) The total time spent in the open arms of the maze by treatment groups. The group
receiving the highest dose of limonene (L2KV) and all Limonene-CBD combination groups spent
significantly more time in the open arms compared to the VV group. Compared to the CBD only
groups (VCBD(1) and VCBD(5)) and the group receiving the lowest dose of limonene (L200V), all
Limonene-CBD combination groups spent significantly more time in the open arms C) The total
number of open arm entries by treatment groups during the 10-minute test. The group receiving the
highest dose of limonene (L2KV) and all Limonene-CBD combination groups (except L200CBD(1))
made significantly more entries than the VV group. Compared to the VCBD(1) group, all LimoneneCBD combination groups (except L200CBD(1)) made significantly more entries. Additionally, the
groups receiving the highest dose of CBD and limonene (L2KCBD(5)) made significantly more entries
than the VCBD(5) group. Single annotation = p ≤ 0.05, double annotation = p ≤ .01, triple annotation
= p ≤ .001. CBD doses were 1 ng/0.5 μL (CBD(1)) or 5 ng/0.5 μL (CBD(5)); limonene doses were 200
μL (L200) or 2000 μL (L2K). Plotted values are the mean ± SEM; the sample size of each group is
represented on the bottom of their respective bar.
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3.2.3 Three-Chamber Social Interaction (SI)
The three-chamber social interaction test was conducted as a pre-clinical
model of social anxiety. Rodents normally prefer to spend time with a conspecific
than alone and also tend to prefer a novel conspecific than a familiar one. Thus, the
assay consists of two measurements: general sociability and preference for social
novelty. These are quantified as ‘social motivation index’ and ‘social recognition
index’, respectively. For this test, the number of animals in each group (excluding
histological outliers mentioned in 2.6 Histology) were: VV [9], VCBD(5) [9], L200V
[10], L2KV [11], L200CBD(5) [10], and L2KCBD(5) [10].
Social Motivation Index (SMI)
The social motivation index is the normalized value of the time spent sniffing
the cage with the rat divided by the total time spent sniffing in Stage Two.
There were no significant differences in the SMI values between any of the
treatment groups based on a one-way ANOVA analysis (F(5,51) = 0.789, p = .563;
Figure 11B). Statistical outliers were identified and removed from the following
group: L2KV [2].
Social Recognition Index (SRI)
The social recognition index is the normalized value of the time spent sniffing
the cage with the novel rat divided by the total time spent sniffing in Stage Three.
There were no significant differences in the SRI values between any of the treatment
groups based on a one-way ANOVA analysis (F(5,54) = 0.065, p = .997; Figure 11C).
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A) Social Interaction Test
Schematic

Figure 11: Social Interaction (Baseline Cohort). A) A front-view schematic of the
SI apparatus B) The social motivation indices measured in Stage Two of the test. No
significant differences were observed between treatment groups; one-way ANOVA
C) The social recognition indices measured in Stage Three of the test. No significant
differences were observed between treatment groups; one-way ANOVA. CBD doses
were 5 ng/0.5 μL (CBD(5)); limonene doses were 200 μL (L200) or 2000 μL (L2K).
Plotted values are the mean ± SEM; the sample size of each group is represented on
the bottom of their respective bar; p < 0.05.
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3.2.4 Light-Dark Box (LDB)
The light-dark box test was used to assess rodents’ inherent aversion for brightlylit spaces. Subjects that spend more time in the light compartment are deemed to be
less anxious. Three parameters from this test were analyzed: time in light, time in
dark, and risk assessment. For this test, the number of animals in each group
(excluding histological outliers mentioned in 2.6 Histology) were: VV [9], VCBD(5)
[8], L200V [8], L2KV [9], L200CBD(5) [9], and L2KCBD(5) [9].
Time in Light
Both the L200CBD(5) and L2KCBD(5) groups spent significantly more time
in the light compartment of the box compared to VV (p = .007 and p = .001,
respectively) and VCBD(5) (p = 0.005 and p < .001, respectively) based on a one-way
ANOVA analysis (F(5, 46) = 4.217, p = 0.003; Figure 12A).
Time in Dark
Compared to the VV treatment group, L200V, L2KV, L200CBD(5), and
L2KCBD(5) spent significantly more time in the dark compartment of the box (p =
.016, p = .002, p < .001, and p < .001, respectively). Additionally, compared to the
VCBD(5) group significant differences were found with L200V, L2KV,
L200CBD(5), and L2KCBD(5) (p = .018, p = .003, p < .001, and p < .001,
respectively); one-way ANOVA analysis (F(5, 45) = 6.814, p < .0001; Figure 12B). It
should be clarified that time in dark is not simply the opposite of time in light as
instances of risk assessment behaviour (see below) are not included in this analysis.
Statistical outliers were identified and removed from the following group:
L200CBD(5) [1].
Risk Assessment

51
The risk assessment measure included (time the subject spent in the light) +
(time the subject spent with its head or forepaws in the light while the body remained
in the dark). Compared to the VV treatment group, L200V, L2KV, L200CBD(5), and
L2KCBD(5) spent significantly more time in risk assessment behaviours (p = .016, p
= .002, p < .0001, p < .0001, respectively). Compared to the VCBD(5) group, L200V,
L2KV, L200CBD(5), and L2KCBD(5) displayed significantly more risk assessment
(p = .018, p = .003, p < .0001, p < .0001, respectively); one-way ANOVA analysis
(F(5, 45) = 6.814, p < .0001; Figure 12C). Statistical outliers were identified and
removed from the following group: L200CBD(5) [1].
Total Number of Transitions
Analysis of the total number of transitions made between the light and dark
compartments revealed a significant difference between the VV group and L2KV (p =
.013), L200CBD(5) (p = .007), and L2KCBD(5) (p = .002) and between the VCBD(5)
group and L2KCBD(5) (p = .022) according to the Kruskal-Wallis test (χ2(5) = 14.52,
p = .013; Figure 12D).
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A) Light-Dark Box Schematic

Figure 12: Light Dark Box (Baseline Cohort). A) A top-down view schematic of the
LDB apparatus B) The total time spent in the light compartment of the box by treatment
groups. Limonene-CBD combination groups spent significantly more time in the light
compared to VV and VCBD(5) groups C) The total time spent in the dark compartment of
the box by treatment groups. Limonene only and Limonene-CBD combination groups
spent significantly less time in the dark compared to VV and VCBD(5) groups. Single
annotation = p ≤ 0.05, double annotation = p ≤ .01, triple annotation = p ≤ .001. CBD
doses were 5 ng/0.5 μL; limonene doses were 200 μL (L200) or 2000 μL (L2K). Plotted
values are the mean ± SEM; the sample size of each group is represented above their
respective error bar.
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Figure 13 (continued): Light Dark Box (Baseline Cohort). D) The total time
spent in risk assessment behaviours. Limonene only and Limonene-CBD
combination groups spent significantly more time in these behaviours compared
to VV and VCBD(5) groups E) The total number of transitions made between the
light and dark compartments during the 10-minute test. L2KV and LimoneneCBD groups made significantly more transitions compared to the VV group.
Additionally, the L2KCBD(5) group made significantly more transitions
compared to the VCBD(5) group. Single annotation = p ≤ 0.05, double annotation
= p ≤ .01, triple annotation = p ≤ .001. CBD doses were 5 ng/0.5 μL; limonene
doses were 200 μL (L200) or 2000 μL (L2K). Plotted values are the mean ±
SEM; the sample size of each group is represented above their respective error
bar.
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3.2.5 Contextual Fear Conditioning (CFC)
The contextual fear conditioning paradigm assesses rodents’ associative memory
between an aversive foot-shock stimulus and the environment. Specifically, this study
assessed rodents’ fear-related memory acquisition. The parameter measured was
freezing behaviour in response to the foot-shock-associated context. For this test, the
number of animals in each group (excluding histological outliers mentioned in 2.6
Histology) were: VV [9], VCBD(1) [10], VCBD(5) [9], L200V [9], L2KV [8],
L200CBD(1) [9], L200CBD(5) [9], and L2KCBD(1) [8].
Freezing Behaviour
All treatment groups (except for VCBD(1)) displayed significantly less time
freezing compared to the VV group. Individuals p values respectively, for VCBD(5),
L200V, L2KV, L200CBD(1), L200CBD(5), and L2KCBD(1) were: .037, .008, .020,
.005, .017, and .002; Kruskal-Wallis test (χ2(7) = 13.45, p = .061; Figure 13B).
Additionally, based on the Welch’s t-test the L2KCBD(1) group spent significantly
less time freezing compared to the VCBD(1) group; (t(16) = 2.245, p = .045; Figure
13B).
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A) Contextual Fear Conditioning
Schematic

Figure 14: Contextual Fear Conditioning (Baseline Cohort). A) A schematic of
the CFC paradigm B) Total time spent freezing in response to the foot-shock
associated environment on Day 2. Compared to the VV group, all groups (except for
VCBD(1)) spent significantly less time freezing. Compared to the VCBD(1) group,
the L2KCBD(1) group spent significantly less time freezing. Single annotation = p ≤
0.05, double annotation = p ≤ .01, triple annotation = p ≤ .001. CBD doses were 1
ng/0.5 μL (CBD(1)) or 5 ng/0.5 μL (CBD(5)); limonene doses were 200 μL (L200)
or 2000 μL (L2K). Plotted values are the mean ± SEM; the sample size of each
group is represented above their respective error bar.
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3.3 NAD299 Challenge Cohort Behavioural Results
3.3.1 Open Field (OF)
The open field (OF) test was conducted to assess if treatment groups affected
general locomotor activity. For this test, the number of animals in each group
(excluding histological outliers mentioned in 2.6 Histology) were: VV [9],
L200CBD(5) [11], L2KCBD(5) [9], L200CBD(5)NAD [11], L2KCBD(5)NAD [11],
and VNAD [11].
General Locomotion
There were no significant differences in the distance travelled between any of
the treatment groups based on a one-way ANOVA analysis (F(4,45) = 0.369, p = .829;
Figure 14A [left]), suggesting that treatment did not affect general locomotion. Thus,
the results from the OF test conclusively eliminated differing locomotor activity as a
confounding variable in all subsequent behavioural assays in the NAD299 challenge
experiments. Additionally, the Welch’s t-test with VV and VNAD confirmed that
locomotor ability did not differ significantly between these groups (t(18) = 1.032, p =
.318; Figure 14A [right]). Statistical outliers were identified and removed from the
following group: L200CBD(5) [1].
Center Time
The time spent in the center of the chamber was analyzed as a measure of
rodent open-space anxiety. There were no significant differences in the time spent in
the center of the chamber between any of the treatment groups based on the KruskalWallis test (χ2(4) = 2.855, p = .582; Figure 14B [left]). Notably, however, the time
spent in the center of the chamber was highest for the Limonene-CBD combination
groups with a trend in the reversal of this effect in the groups receiving NAD299.
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Additionally, there was no significant difference in the time spent in the center
between the VV and VNAD groups based on the Mann-Whitney test (U = 33, p =
.356; Figure 14B [right]). Statistical outliers were identified and removed from the
following groups: L200CBD(5)NAD [1] and VNAD [1].
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Figure 15: Open Field (NAD299 Challenge Cohort). A) Left: The distance travelled in
the first five minutes of the test. No significant differences were observed between
treatment groups; one-way ANOVA A) Right: The distance travelled between VV and
VNAD groups. No significant differences were observed between groups; Welch’s t-test
B) Left: Time spent in the center of the apparatus in the first five minutes of the test. No
significant differences were observed between groups; K-S test B) Right: Time spent in
the center between VV and VNAD groups. No significant differences were observed
between groups; Mann-Whitey U-test. CBD doses were 5 ng/0.5 μL (CBD(5)); limonene
doses were 200 μL (L200) or 2000 μL (L2K); NAD299 doses were 100 ng/0.5 μL. Plotted
values are the mean ± SEM; the sample size of each group is represented on the bottom of
their respective bar; p < 0.05.
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3.3.2 Elevated Plus Maze (EPM)
The elevated plus maze test was used to assess rodents’ inherent aversion to open
spaces. Subjects that spend more time in the open arms of the maze are deemed to be
less anxious. Two parameters from this test were analyzed: time in open arms and the
total number of open arm entries. For this test, the number of animals in each group
(excluding histological outliers mentioned in 2.6 Histology) were: VV [9],
L200CBD(1) [8], L200CBD(5) [13], L2KCBD(1) [8], L2KCBD(5) [9],
L200CBD(5)NAD [8], L2KCBD(5)NAD [8], and VNAD [8]. Animals that fell off
the maze and therefore, did not complete the 10-minute assay were excluded from
analysis. These were from: VV [1] and L200CBD(5) [2].
Time in Open Arms
In comparison to the VV group, all Limonene-CBD combination groups (i.e.,
L200CBD(1), L200CBD(5), L2KCBD(1), and L2KCBD(5)) spent significantly more
time in the open arms of the maze; p = .016, p = .005, p = .012, and p = .016,
respectively. Additionally, there appeared to be a reversal of this affect with NAD299
as displayed by the significant difference between L200CBD(1) and
L200CBD(5)NAD (p = .012), L200CBD(1) and L2KCBD(5)NAD (p = .035),
L200CBD(5) and L200CBD(5)NAD (p = .004), L200CBD(5) and L2KCBD(5)NAD
(p = .013), L2KCBD(1) and L200CBD(5)NAD (p = .009), L2KCBD(1) and
L2KCBD(5)NAD (p = .028), L2KCBD(5) and L200CBD(5)NAD (p = .012), and
L2KCBD(5) and L2KCBD(5)NAD (p = .036). Figure 15A [left] illustrates these
results; one-way ANOVA analysis (F(6, 53) = 3.774, p = .003). The Welch’s t-test
revealed no significant difference between the VV and VNAD groups (t(14) = 1.151, p
= .271; Figure 15A [right]).
Total Number of Open Arm Entries
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In comparison to the VV group, L200CBD(5), L2KCBD(1), and L2KCBD(5)
groups made significantly more open arm entries (p = .018, p = .025, and p = .011,
respectively). Additionally, there was a significant reversal of this effect with
NAD299 with decreased open arm entries in the L200CBD(5)NAD group compared
to the L2KCBD(5) group (p = .038). Figure 15B [left] summarizes these findings;
one-way ANOVA analysis (F(6, 53) = 2.238, p = .054). The Welch’s t-test revealed no
significant difference between the VV and VNAD groups (t(14) = .674, p = .512;
Figure 15B [right]).
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Figure 16: Elevated Plus Maze (NAD299 Challenge Cohort). A) Left: Total time spent in the
open arms of the maze by treatment groups. Compared to the VV group, all Limonene-CBD
combination groups spent significantly more time in the open arms. There was a reversal of this
effect illustrated by the groups receiving NAD299 spending significantly less time in the open
arms compared to the Limonene-CBD combination groups A) Right: Graph displaying no
significant differences in the total time spent in the open arms of the maze between VV and
VNAD groups B) Left: Total number of open arm entries by treatment groups during the 10minute test. Compared to the VV group, all Limonene-CBD combination groups (except
L200CBD(1)) made significantly more entries. Additionally, the L200CBD(5)NAD group made
significantly fewer entries than the L2KCBD(5) group B) Right: Graph displaying no significant
difference in the total number of open arm entries between VV and VNAD groups. Single
annotation = p ≤ 0.05, double annotation = p ≤ .01, triple annotation = p ≤ .001. CBD doses were
1 ng/0.5 μL (CBD(1)) or 5 ng/0.5 μL (CBD(5)); limonene doses were 200 μL (L200) or 2000 μL
(L2K); NAD299 doses were 100 ng/0.5 μL. Plotted values are the mean ± SEM; the sample size
of each group is represented on the bottom of their respective bar.
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3.3.3 Three Chamber Social Interaction (SI)
The three-chamber social interaction test was conducted as a pre-clinical model of
social anxiety. Rodents normally prefer to spend time with a conspecific than alone
and also tend to prefer a novel conspecific than a familiar one. Thus, the assay
consists of two measurements: general sociability and preference for social novelty.
These are quantified as ‘social motivation index’ and ‘social recognition index’,
respectively. For this test, the number of animals in each group (excluding
histological outliers mentioned in 2.6 Histology) were: VV [9], L200CBD(5) [10],
L2KCBD(5) [10], L200CBD(5)NAD [9], L2KCBD(5)NAD [9], and VNAD [10].
Social Motivation Index (SMI)
The social motivation index is the normalized value of the time spent sniffing
the cage with the rat divided by the total time spent sniffing in Stage Two. There were
no significant differences in the SMI values between any of the treatment groups
based on a one-way ANOVA analysis (F(4,42) = 0.290, p = .883; Figure 16A [left]).
Additionally, the Welch’s t-test with VV and VNAD confirmed that social motivation
indices did not differ significantly between these groups (t(17) = 1.753, p = .098;
Figure 16A [right]).
Social Recognition Index (SRI)
The social recognition index is the normalized value of the time spent sniffing
the cage with the novel rat divided by the total time spent sniffing in Stage Three.
There were no significant differences in the SRI values between any of the treatment
groups based on a one-way ANOVA analysis (F(4,43) = 0.329, p = .857; Figure 16B
[left]). Additionally, the Welch’s t-test with VV and VNAD confirmed social
recognition indices did not differ significantly between these groups (t(18) = 1.217, p =
.0239; Figure 16B [right]).
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Figure 17: Social Interaction (NAD299 Challenge Cohort). A) Left: Social motivation indices
measured in Stage Two of the test. No significant differences were observed between treatment
groups; one-way ANOVA A) Right: No significant difference in social motivation indices
between VV and VNAD; Welch’s t-test B) Left: Social recognition indices measured in Stage
Three of the test. No significant differences were observed between treatment groups; one-way
ANOVA B) Right: No significant difference in social recognition indices between VV and
VNAD; Welch’s t-test. CBD doses were 5 ng/0.5 μL (CBD(5)); limonene doses were 200 μL
(L200) or 2000 μL (L2K); NAD299 doses were 100 ng/0.5 μL. Plotted values are the mean ±
SEM; the sample size of each group is represented on the bottom of their respective bar; p < 0.05.
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3.3.4 Light-Dark Box (LDB)
The light-dark box test was used to assess rodents’ inherent anxiety for brightly-lit
spaces. Three parameters from this test were analyzed: time in light, time in dark, and
risk assessment. For this test, the number of animals in each group (excluding
histological outliers mentioned in 2.6 Histology) were: VV [9], L200CBD(5) [9],
L2KCBD(5) [9], L200CBD(5)NAD [12], L2KCBD(5)NAD [12], and VNAD [11].
Time in Light
Both the L200CBD(5) and L2KCBD(5) groups spent significantly more time
in the light compartment of the box compared to VV (p = .014 and p = .003,
respectively; one-way ANOVA analysis (F(4, 46) = 2.917, p = .031); Figure 17A
[left]). The Mann-Whitney test revealed no significant difference between the VV and
VNAD groups (U = 48, p = .941; Figure 17A [right]). Statistical outliers were
identified and removed from the following group: L2KCBD(5)NAD [1].
Time in Dark
Compared to the VV treatment group, L200CBD(5), and L2KCBD(5) spent
significantly more time in the dark compartment of the box (p = .005 and p = .002,
respectively). Additionally, there was a significant reversal of this effect with
NAD299 as observed by the significant difference between L200CBD(5) and
L200CBD(5)NAD (p = .048) and L2KCBD(5) and L200CBD(5)NAD (p = .022);
one-way ANOVA analysis (F(4, 44) = 3.864, p = .009; Figure 17B [left]). The MannWhitney test revealed no significant difference between the VV and VNAD groups
(U = 44, p = .710; Figure 17B [right]). It should be clarified that time in dark is not
simply the opposite of time in light as instances of risk assessment behaviour (see
below) are not included in this analysis. Statistical outliers were identified and
removed from the following groups: L200CBD(5) [1] and L2KCBD(5)NAD [1].
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Risk Assessment
The risk assessment measure included (time the subject spent in the light) +
(time the subject spent with its head or forepaws in the light while the body remained
in the dark). Compared to the VV treatment group, L200CBD(5), L2KCBD(5), and
L2KCBD(5)NAD spent significantly more time in risk assessment behaviours (p =
.009, p = .004, p < .019, respectively). Compared to the L2KCBD(5) group, the
L2KCBD(5)NAD displayed significantly less risk assessment (p = .037); one-way
ANOVA analysis (F(4, 45) = 3.378, p = .017; Figure 17C [left]). The Mann-Whitney
test revealed no significant difference between the VV and VNAD groups (U = 44, p
= .710; Figure 17C [right]). Statistical outliers were identified and removed from the
following group: L200CBD(5) [1].
Total Number of Transitions
Analysis of the total number of transitions made between the light and dark
compartments revealed a significant difference between VV and L200CBD(5) (p =
.004), VV and L2KCBD(5) (p = .001), and L2KCBD(5) and L2KCBD(5)NAD
groups (p = .030); Kruskal-Wallis test (χ2(4) = 14.09, p = .007; Figure 17D [left]). The
Mann-Whitney test revealed no significant difference between the VV and VNAD
groups (U = 47.5, p = .901; Figure 17D [right].
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Figure 18: Light Dark Box (NAD299 Challenge Cohort). A) Left: Total time spent in the light
compartment of the box by treatment groups. Limonene-CBD combination groups spent significantly
more time in the light compared to the VV group A) Right: Graph displaying no significant
differences in the total time spent in the light compartment of the box between VV and VNAD groups
B) Left: Total time spent in the dark compartment of the box by treatment groups. Limonene-CBD
combination groups spent significantly less time in the dark compared to the VV group. Additionally,
the L200CBD(5)NAD group displayed significantly more time in the dark compared to both the
Limonene-CBD combination groups B) Right: Graph displaying no significant differences in the total
time spent in the light compartment of the box between VV and VNAD groups. Single annotation = p
≤ 0.05, double annotation = p ≤ .01, triple annotation = p ≤ .001. CBD doses were 5 ng/0.5 μL;
limonene doses were 200 μL (L200) or 2000 μL (L2K); NAD299 doses were 100 ng/0.5 μL. Plotted
values are the mean ± SEM; the sample size of each group is represented on the bottom of their
respective bar.
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Figure 19 (continued): Light Dark Box (NAD299 Challenge Cohort). C) Left: Graph displaying
significant differences in risk assessment between VV and Limonene:CBD combination groups and the
L2KCBD(5)NAD group, and between the L2KCBD(5) and L200CBD(5)NAD groups C) Right: Graph
displaying no significant differences in risk assessment between VV and VNAD groups D) Left: Total
number of transitions made between the light and dark compartments during the 10-minute test. LimoneneCBD groups made significantly more transitions compared to the VV group. The L200CBD(5)NAD group
displayed significantly less transitions than the L2KCBD(5) group D) Right: Graph displaying no significant
differences in the total number of transitions made between VV and VNAD groups. Single annotation = p ≤
0.05, double annotation = p ≤ .01, triple annotation = p ≤ .001. CBD doses were 5 ng/0.5 μL; limonene doses
were 200 μL (L200) or 2000 μL (L2K); NAD299 doses were 100 ng/0.5 μL. Plotted values are the mean ±
SEM; the sample size of each group is represented on the bottom of their respective bar.
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3.3.5 Contextual Fear Conditioning (CFC)
The contextual fear conditioning paradigm assesses rodents’ associative memory
between an aversive foot-shock stimulus and the environment. Specifically, this study
assessed rodents’ fear-related memory acquisition. The parameter measured was
freezing behaviour in response to the foot-shock-associated context. For this test, the
number of animals in each group (excluding histological outliers mentioned in 2.6
Histology) were: VV [9], L200CBD(1) [9], L200CBD(5) [9], L2KCBD(1) [8],
L200CBD(5)NAD [10], L2KCBD(5)NAD [10], and VNAD [9].
Freezing Behaviour
All treatment groups displayed significantly less time freezing compared to
the VV group. Individuals p values respectively, for L200CBD(1), L200CBD(5),
L2KCBD(1), L200CBD(5)NAD, and L2KCBD(5)NAD were: .004, .015, .002, .005,
and .014. Notably, groups receiving NAD299 displayed a trend of greater freezing
time compared to the Limonene-CBD combination groups. These findings are
illustrated in Figure 18A [left]; Kruskal-Wallis test (χ2(5) = 13.22, p = .021). The VV
and VNAD groups displayed no significant difference in freezing time; MannWhitney test (U = 23, p = .136; Figure 18A [right]).
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Figure 20: Contextual Fear Conditioning (NAD299 Challenge Cohort). A) Left: Total time spent freezing
in response to the foot-shock associated environment on Day 2. Compared to the VV group, all groups spent
significantly less time freezing. A) Right: VV and VNAD groups did not differ significantly in freezing time.
Single annotation = p ≤ 0.05, double annotation = p ≤ .01, triple annotation = p ≤ .001. CBD doses were 1
ng/0.5 μL (CBD(1)) or 5 ng/0.5 μL (CBD(5)); limonene doses were 200 μL (L200) or 2000 μL (L2K); NAD299
doses were 100 ng/0.5 μL. Plotted values are the mean ± SEM; the sample size of each group is represented on
the bottom of their respective bar.
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3.4 Molecular Assays
Downstream molecular biomarkers associated with anxiety and the 5-HT1A
system were quantified to elucidate potential mechanisms of action of the
formulations utilized in the behavioural assays. Three brain regions were analyzed:
the PFC, NASh, and BLA. One-way ANOVA analyses were conducted with protein
expression levels normalized to the control group (VV) and represented as a
percentage out of 100.
3.4.1 Mitogen-Activated Protein Kinase Pathway (ERK 1/2)
Prefrontal Cortex
With regards to the ERK1 isoform in the PFC, p-ERK1 levels were
significantly lower in the L2KCBD(5) group in comparison to the VV and VCBD(5)
groups (F(3, 12) = 5.482, p = .013; p = .006 and p = .005, respectively; Figure 19A). TERK1 expression was significantly higher in the VCBD(5) and L2KCBD(5) groups
compared to VV (F(3, 12) = 2.216, p = .139; p = .044 and p = .048, respectively; Figure
19B). The ratio of p/T ERK1 levels were significantly lower in the L2KCBD(5) group
and the L2KCBD(5)NAD group compared to the VV group (F(3, 12) = 9.810, p = .002;
p < .001 and p = .006, respectively; Figure 19C) and additionally, L2KCBD(5)
displayed significantly lower p/T ERK1 levels relative to the VCBD(5) group (p =
.005; Figure 19C).
Comparing the expression of the ERK2 isoform demonstrated that p-ERK2
levels were significantly lower in the L2KCBD(5) group compared to the VV and
VCBD(5) groups (χ2(3) = 10.55, p = .003; p = .004 and p = .009, respectively; Figure
19A). There were no significant differences in the T-ERK2 levels between treatment
groups (F(3, 12) = 1.432, p = .282; Figure 19B). p/T ERK2 levels were significantly
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lower in L2KCBD(5) group compared to the VV and VCBD(5) groups (F(3, 12) =
10.19, p = .001; p < .001 and p = .002 respectively; Figure 19C) and in the
L2KCBD(5)NAD group compared to the VV and VCBD(5) groups (p = .004 and p =
.028, respectively; Figure 19C). Each treatment group contained tissue samples from
4 animals.
Nucleus Accumbens Shell
Within the NASh, no significant differences were found in any measures of
the ERK1 isoform (p-ERK1: F(3, 16) = 1.590, p = .231 [Figure 19D]; T-ERK1: F(3, 16)
= 0.127, p = .943 [Figure 19E]; p/T-ERK1: F(3, 15) = 1.264, p = .322 [Figure 19F]).
ERK2 isoform expression levels were significantly lower for p-ERK2 in the
VCBD(5), L2KCBD(5), and L2KCBD(5)NAD groups compared to the VV group
(F(3, 15) = 5.093, p = .013; p = .022, p = 002, and p = .041, respectively; Figure 19D).
No significant differences were found in the T-ERK2 levels between groups (F(3, 15) =
0.107, p = .955; Figure 19E), while p/T ERK2 was significantly lower only in the
L2KCBD(5) group relative to the VV group (F(3, 15) = 2.185, p = .132; p = .024;
Figure 19F). Each treatment group contained tissue samples from 5 animals.
Statistical outliers were identified using the Grubbs’ Test and removed from the
following groups: one L2KCBD(5) sample from p-ERK2 and T-ERK2 and one
VCBD(5) sample from p/T-ERK1.
Basolateral Amygdala
Quantification in the BLA revealed no significant differences in any measures
of the ERK1 isoform (p-ERK1: F(3, 10) = 1.030, p = .420 [Figure 19G]; T-ERK1: F(3,
10)

= 0.579, p = .642 [Figure 19H]; p/T-ERK1: F(3, 10) = 0.847, p = .499 [Figure 19I]).
Similarly, p-ERK2 levels did not display significant differences between

groups (F(3, 10) = 1.080, p = .401; Figure 19G) while T-ERK2 was only significantly
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lower in the L2KCBD(5)NAD group compared to the VV group (F(3, 10) = 1.698, p =
.230; p = .048; Figure 19H). Finally, there were no differences in the p/T ERK2
levels (F(3, 10) = 1.609, p = .249; Figure 19I). Each treatment group contained tissue
samples from 4 animals. Statistical outliers were identified using the Grubbs’ Test and
removed from the following groups: one L2KCBD(5) sample from p-ERK1/2 and TERK1/2 and one L2KCBD(5)NAD sample from p-ERK1/2 and T-ERK1/2.
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Mitogen-Activated Protein Kinase Pathway (ERK 1/2)
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Figure 21: ERK Expression Levels Within the PFC, NASh, and BLA. PFC: A) p-ERK1 and
2 were significantly lower in the L2KCBD(5) group compared to VV and VCBD(5) B) T-ERK1
was significantly higher in the VCBD(5) and L2KCBD(5) groups compared to VV C) p/TERK1 and 2 were significantly lower in the L2KCBD(5) group compared to VV and VCBD(5).
The L2KCBD(5)NAD group displayed significantly lower p/T-ERK1 and 2 compared to VV
and significantly lower p/T-ERK2 compared to VCBD(5). NASh: D) p-ERK2 was significantly
lower in the VCBD(5), L2KCBD(5), and L2KCBD(5)NAD groups compared to VV E) No
significant differences were observed in the T-ERK1 and 2 levels between treatment groups F)
p/T- ERK2 was significantly lower in the L2KCBD(5) group compared to VV. BLA: G) No
significant differences were found between treatment groups in p-ERK1 and 2 expression H) TERK2 was significantly lower in the L2KCBD(5)NAD group compared to VV I) No significant
differences were observed in the p/T-ERK1 and 2 levels between treatment groups. J, K, L)
Representative Western blots of J) PFC, K) NASh, and L) BLA showing p-ERK1-2, T-ERK12, and α-tubulin expression. Separate one-way ANOVA analyses were conducted as indicated
by the dotted vertical lines. Single annotation = p ≤ 0.05, double annotation = p ≤ .01, triple
annotation = p ≤ .001. All CBD doses were 5 ng/0.5 μL; limonene doses were 2000 μL (L2K);
the NAD299 dose was 100 ng/0.5 μL. Plotted values are the mean ± SEM; the sample size of
each group is represented on the bottom of their respective error bar.
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3.4.2 PI3K-Akt Signal Transduction Pathway (Akt Ser473)
Prefrontal Cortex
No significant differences were found between treatment groups in any
quantifications of Akt Ser473 within the PFC (p-AktSer473: F(3, 12) = 0.132, p = .940
[Figure 20A]; T-Akt Ser473: F(3, 12) = 0.060, p = .980 [Figure 20B]; p/T-Akt Ser473
F(3, 12) = 0.068, p = .976 [Figure 20C]). Each treatment group contained tissue
samples from 4 animals.
Nucleus Accumbens Shell
No significant differences were found in the total Akt levels in the
NASh (T-Akt Ser473: F(3, 15) = 0.235, p = .870; Figure 20E). However, p-Akt Ser 473
was significantly lower in the L2KCBD(5) group compared to the VV, VCBD(5), and
L2KCBD(5)NAD groups (F(3, 15) = 4.782, p = .016; p = .004, p = .049, and p = .006,
respectively; Figure 20D). Moreover, p/T Akt Ser473 was significantly lower in the
L2KCBD(5) group compared VV (F(3, 15) = 1.760, p = .198; p = .045; Figure 20F).
Each treatment group contained tissue samples from 5 animals. Statistical outliers
were identified using the Grubbs’ Test and removed from the following groups: one
L2KCBD(5) sample from p-Akt Ser473 and T-Akt Ser473.
Basolateral Amygdala
No significant differences were observed between treatment groups within the
BLA in T-Akt Ser 473 levels (F(3, 12) = 0.810, p = .513; Figure 20H) and in P/T-Akt
Ser 473 levels levels (F(3, 12) = 1.890, p = .185; Figure 20I). However, p-Akt Ser 473
was significantly lower in the L2KCBD(5) group compared to the VV group (F(3, 12)
= 2.203, p = .141; p = .038; Figure 20G). Each treatment group contained tissue
samples from 4 animals.
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PI3K-Akt Signal Transduction Pathway (Akt Ser 473)
A)

B)

D)

E)

G)

J)

C)

F)

I)

H)

K)

L)

Figure 22: Akt Ser 473 Expression Levels Within the PFC, NASh, and BLA. PFC: No
significant differences were found in the A) p-Akt Ser473, B) T-Akt Ser 473, and C) p/T-Akt Ser
473 levels within the PFC. NASh: D) L2KCBD(5) displayed significantly lower p-Akt Ser 473
compared to VV, VCBD(5), and L2KCBD(5)NAD groups E) No significant differences were
found in the T-Akt Ser 473 levels between treatment groups F) The L2KCBD(5) group exhibited
significantly lower p/T-Akt Ser 473 levels compared to VV BLA: G) p-Akt Ser 473 was
significantly lower in the L2KCBD(5) groups compared to VV H) No significant differences were
found in the T-Akt SER 473 levels between treatment groups I) No significant differences were
found in the p/T-Akt Ser 473 levels between treatment groups. J, K, L) Representative Western
blots of J) PFC, K) NASh, and L) BLA showing p-Akt Ser 473, T-Akt Ser 473, and α-tubulin
expression. One-way ANOVA analysis. Single annotation = p ≤ 0.05, double annotation = p ≤ .01,
triple annotation = p ≤ .001. All CBD doses were 5 ng/0.5 μL; limonene doses were 2000 μL
(L2K); the NAD299 dose was 100 ng/0.5 μL. Plotted values are the mean ± SEM; the sample size
of each group is represented above their respective error bar.
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4. Discussion
Previous evidence has alluded to the synergistic potential of cannabis-derived
compounds in modulating mental and physical states (Russo, 2011). This
phenomenon generally referred to as the ‘Entourage Effect’ (EE), has not yet been
explored with regards to combinatorial administrations of cannabidiol (CBD) and dlimonene. By utilizing a rodent model, this thesis demonstrated for the first time the
synergistic potential and greater anxiolytic efficacy of Limonene-CBD formulations
relative to isolated administrations of CBD or limonene, specifically within the
nucleus accumbens shell (NASh) brain region (Aim 1). Additionally, by utilizing a
molecular antagonist (NAD299) and via analysis of specific molecular markers, this
study elucidated the potential 5-HT1A-mediated mechanism of these Limonene-CBD
formulations (Aim 2), as well as changes in specific downstream signalling molecules
associated with this activation (Aim 3).
Overall, the greater reduction of anxiety-related symptoms in behavioural
assays in the Limonene-CBD groups relative to isolated groups of CBD or limonene
supported the proposed hypothesis of EE-potentiated anxiolysis in Limonene-CBD
formulations. Moreover, Western blots demonstrating the differential protein
expression levels exhibited by isolated CBD relative to the Limonene-CBD
combinatorial group allude to a distinctive mechanism in the modulation of neuronal
activity that likely underlies this synergism.
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4.1 Baseline Cohort: Limonene-CBD Demonstrate EE-Potentiated Anxiolysis
Table 2: Summary of Baseline Cohort Behavioural Results
Behavioural Test

Limonene-CBD groups
relative to isolated CBD or
Limonene groups
No difference in locomotion
No difference in center time

Conclusion

Elevated-Plus Maze

Increase in time spent in
open arms and total number
of open arm entries

EE-potentiated
anxiolysis

Social Interaction

No differences in social
motivation index or social
recognition index

-

Light-Dark Box

Increase in time spent in
light compartment and total
number of compartmental
transitions
Decrease in time spent in
dark compartment

EE-potentiated
anxiolysis

Contextual Fear
Conditioning (Memory
Acquisition)

Decrease in freezing time

EE-potentiated
anxiolysis

Open-Field

-

The CBD doses of 1 ng/0.5 μL and 5 ng/0.5 μL utilized in this cohort were
deemed to be sub-threshold doses in modulating anxiety-related behaviour based on
previous literature on intra-NASh microinfusions in rats (Norris et al., 2016). An
exception was in the contextual fear conditioning test, where 5 ng/0.5 μL of CBD
proved to be an effective dose. The volumes of limonene, 200 μL and 2000 μL, were
established from a study by Harada et al. (2018) assessing the anxiolytic effects of a
similar monoterpene, linalool. Consequently, for this thesis, significant reduction in
anxiety-related measures in the Limonene-CBD groups relative to the CBD or
limonene alone group suggested synergistic effects and thereby, EE-potentiated
anxiolysis.
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The open-field (OF) test was conducted primarily to assess for potential
locomotor variations evoked by the drug assays. Analysis of the first five minutes of
the test yielded no significant differences between the treatment groups in the total
distance travelled consistent with previous findings on CBD (Kasten et al., 2019;
Long et al., 2010) and with inhaled limonene (Satou et al., 2012). Critically, this
outcome suggested that changes in anxiety-related behaviours observed in other
experimental assays are unlikely to be mediated by alterations in motor functionality
and can be more confidently associated with modulation within the limbic system.
The secondary measure of center time in the first five minutes of the OF test
yielded no significant differences between treatment groups consistent with previous
findings for intraperitoneally administered CBD (Kasten et al., 2019). Although we
observed a trend of increased center time in the Limonene-CBD groups, the similar
levels of anxiolysis found in the isolated CBD and limonene groups suggest that
Limonene-CBD synergy was not established in this test. Conversely, it is plausible
that 5 ng/0.5 μL of CBD and 2000 μL limonene are suprathreshold doses in this
assay, and thus utilizing a dose of 1 ng/0.5 μL of CBD may help elucidate potential
synergistic effects.
It should be noted that criticisms exist for the use of the OF test as a reliable
measure of anxiety as it has been shown to be insensitive to some conventional
anxiolytics, such as triazolobenzodiazepines and anti-depressants (Prut & Belzung,
2003). Moreover, findings such as the anxiogenic drug amphetamine showing an
increase in center exploration (Einat, 2006), suggests that there exists some ambiguity
on how center time should be interpreted in this paradigm. Consequently for this
study, the OF test cannot conclusively eliminate the ability of Limonene-CBD
formulations in modulating open-space anxiety.
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The most robust evidence of open-space anxiolysis and synergism between
cannabidiol and limonene was found in the elevated-plus maze (EPM) test, wherein,
all combinations of Limonene-CBD (L200CBD(1), L200CBD(5), L2KCBD(1), and
L2KCBD(5)) resulted in significantly more time spent in the open arms of the maze
relative to the isolated administration of CBD at both experimental doses (VCBD(1)
and VCBD(5)) and relative to the isolated administration of limonene at the lowest
dose (L200V). Moreover, subjects in three of the combinatorial treatment groups
(L200CBD(5), L2KCBD(1), and L2KCBD(5)) made significantly more open arm
entries relative to those in VCBD(1); additionally, the L2KCBD(5) group made
significantly more open arm entries relative to VCBD(5). These findings are
substantiated by prior literature linking limonene to increased values on these
parameters (Gurgel do Vale et al., 2002; Komiya et al., 2006; Lima et al., 2013), as
well as that of cannabidiol (Guimarães et al., 1990).
With regards to the three-chamber social interaction (SI) test, we found no
differences in the social motivation index and the social recognition index values
between treatment groups suggesting a lack of EE-potentiated improvement in social
anxiety and social cognition by the Limonene-CBD formulations. Our SI results are
consistent with previous SI findings demonstrating that isolated CBD does not affect
social interaction (Long et al., 2010; Malone et al., 2009; Szkudlarek et al., 2019; van
Ree et al., 1984). While there are currently no studies assessing the effects of
limonene on this test, evidence using inhaled orange essential oil (OEO) (containing
96.24% limonene) suggests that it may increase active social interaction in this
paradigm (Leite et al., 2008). However, given that OEO contains many components in
addition to limonene, namely: 0.53% alpha-pinene, 0.27% sabinene, 2.24% myrcene,
0.44% linalool, and 0.25% decanal, its reported effects on social interaction could
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also be a result of synergy and thus, explain why we did not find similar effects in
isolated limonene groups (Leite et al., 2008).
Despite the findings of this thesis, the possibility that CBD and limonene
could be effective agents for alleviating social anxiety should not be dismissed.
Research suggests that CBD administration can reverse the social deficits associated
with genetically-altered mouse models of autism (Kaplan et al., 2017) and in THCinduced social withdrawal (Malone et al., 2009). Moreover, while acute CBD may not
significantly improve social interaction, chronic administration can (Osborne et al.,
2017). Thus, while Limonene-CBD formulations did not significantly improve social
interaction in our study, this does not suggest that they will be ineffective in those
already suffering from social anxiety, especially with chronic treatment. Further
studies wherein, Limonene-CBD formulations are administered over an extended
period or in rodent models of social deficit could clarify these effects.
Within the light-dark box (LDB) test, combinatorial groups (L200CBD(5) and
L2KCBD(5)) spent significantly greater time in the light compartment and
significantly less time in the dark compartment in comparison to the VCBD(5) group.
Moreover, the L2KCBD(5) group made significantly more compartmental transitions
relative to the VCBD(5) group. These results imply that CBD and limonene
synergistically alleviate bright-space anxiety in rodents, as expected from previous
reports using effective doses of CBD (Long et al., 2010) and inhaled limonene (Satou
et al., 2012).
Interestingly, the limonene groups (L200V and L2KV) also spent significantly
less time in the dark compared to the VCBD(5) group but did not display a
consequent increase in light time. This discrepancy is a result of the limonene groups
spending significantly more time in risk assessment behaviours (placing nose or
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forepaws into the light compartment from the dark compartment) as opposed to
wholly entering the light area. Taken together then, these findings offer further
support that combining CBD with limonene potentiates limonene’s anxiolytic
efficacy.
Finally, the contextual-fear conditioning (CFC) test, found that all treatment
groups (except VCBD(1)) displayed a significant reduction in freezing time relative to
the VV group. Consequently, for this paradigm, 1 ng/0.5 μL of CBD represents a subthreshold dose (Norris et al., 2016), while 5 ng/0.5 μL is an effective dose as verified
by the significant extinguishment of freezing behaviour within the VCBD(5) group.
Additionally, the significant reduction in freezing exhibited by the L2KCBD(1) group
relative to the VCBD(1) group supports the proposition that CBD and limonene
synergistically attenuate the formation of fear-related memory, and thereby, may be
an effective therapeutic agent in preventing the onset of anxiety-related symptoms,
such as in post-traumatic stress disorder. While there are presently no studies
examining the effect of limonene on contextual fear conditioning, a study by
d’Alessio et al. (2014) found that orally administered d-limonene reversed the onset
of freezing behaviour induced by a stress paradigm. Moreover, the CFC findings of
this study are in agreement with previous work using this paradigm and cannabidiol
(Fogaça et al., 2014; Gomes et al., 2012; Lemos et al., 2010; Resstel et al., 2009) with
some studies utilizing specific receptor antagonists proposing that these effects are
modulated through 5-HT1A-mediated neurotransmission (Fogaça et al., 2014; Gomes
et al., 2012).
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4.2 NAD299 Challenge Cohort: Limonene-CBD EE-Potentiation is 5-HT1ADependent
Table 3: Summary of NAD299 Challenge Behavioural Results
Behavioural Test

Limonene-CBD-NAD vs.
Limonene-CBD
No difference in locomotion
No difference in center time

Conclusion

Elevated-Plus Maze

Decrease in time spent in open
arms and total number of open
arm entries

5-HT1A-dependent
anxiolysis

Social Interaction

No differences in social
motivation index or social
recognition index

-

Light-Dark Box

Decrease in time spent in light
compartment and total number of
compartmental transitions
Increase in time spent in dark
compartment

5-HT1A-dependent
anxiolysis

Contextual Fear
Conditioning (Memory
Acquisition)

No difference in freezing time

-

Open-Field

-

The CBD doses of 1 ng/0.5 μL and 5 ng/0.5 μL utilized in this cohort were
deemed to be sub-threshold doses in modulating anxiety-related behaviour based on
previous literature on intra-NASh microinfusions in rats (Norris et al., 2016). An
exception was in the contextual fear conditioning test, where 5 ng/0.5 μL of CBD
proved to be an effective dose. The volumes of limonene, 200 μL and 2000 μL, were
established from a study by Harada et al. (2018) assessing the anxiolytic effects of a
similar monoterpene, linalool. The utilized antagonist, NAD299, is highly specific in
attenuating 5-HT1A receptor-induced anxiolysis and individual administration of
NAD299 did not by itself modify any of the anxiety-related parameters assessed in

83
this study similar to previous literature findings (Johansson et al., 1997; Norris et al.,
2016; Szkudlarek et al., 2019). Consequently, for this thesis, a reduction in anxietyrelated behaviours in the Limonene-CBD-NAD groups relative to the Limonene-CBD
groups suggested a 5-HT1A receptor-mediated anxiolytic effect.
Discussion of NAD299 Challenge Behavioural Results
In the open field task, the absence of difference in ambulatory distance
between the treatment groups verified that NAD299 does not alter locomotor ability.
Consequently, deviations in anxiety-related measures in subsequent assays within this
cohort were confidently attributed to changes within the limbic system, as opposed to
variability in motor function. Although there was a trend of increased center time in
the Limonene-CBD groups that was reversed by the addition of NAD299 (Figure
14B [left]), our results from the Baseline Cohort showing similar levels of anxiolysis
in the isolated CBD and limonene groups relative to Limonene-CBD groups suggest
that Limonene-CBD synergy was not established in the OF test (Figure 9C). That
said, the perceived trend in the reversal of this effect by NAD299 suggests that any
potential mechanism of anxiolysis is likely mediated by 5-HT1AR. As mentioned
previously, however, there is some uncertainty on how center time should be
interpreted (Einat, 2006; Prut & Belzung, 2003), thus, conclusions about open-space
anxiety from this assay should be made cautiously.
In contrast, the elevated plus maze (EPM) is a well-established test of openspace anxiety. We found a significant EE-potentiated increase in the total time spent
in the open arms for all Limonene-CBD groups that was significantly reduced upon
co-administration of NAD299 in both combinatorial doses (L200CBD(5)NAD and
L2KCBD(5)NAD). Furthermore, there was a reversal of the EE-potentiated increase
in the total number of open arm entries with a significant reduction displayed by the
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L200CBD(5)NAD group compared to the L200CBD(5) group. Taken together, these
results strongly propose that open-space anxiolysis by Limonene-CBD formulations
are mediated by 5-HT1AR consistent with the proposed 5-HT1A mechanism in
previous research on the EPM assay using effectual doses of CBD (de Gregorio et al.,
2019; Szkudlarek et al., 2019) and limonene (Komiya et al., 2006).
The lack of significant differences in the social motivation and social
recognition indices between the Limonene-CBD formulations and the LimoneneCBD-NAD groups in the three-chamber social interaction (SI) test suggests that at
least within the context of this study, CBD, limonene, and NAD do not modulate
measures of rodent social anxiety (for a more detailed discussion of this test see
Discussion of Baseline Cohort Behavioural Results).
In regards to the light dark box (LDB) test, the observed decrease in the time
spent in the light, the decrease in the total number of compartmental transitions, and
the subsequent increase in the time spent in the dark amongst the Limonene-CBDNAD groups relative to the Limonene-CBD groups, signify that the EE-potentiated
anxiolytic effects of CBD and limonene towards bright spaces are 5-HT1AR mediated.
This conclusion is further corroborated by findings by Costa et al. (2013) showing
that the essential oil (EO) extracted from Citrus aurantium (containing 98.66%
limonene) similarly modifies these same LDB parameters with effects being mediated
by the 5-HT1A receptor. Notably, however, these researchers found that the
administration of pure limonene at its prevalent dose within the EO did not modify
these LDB behaviors, implying that the anxiolytic effects of the EO are a result of
synergism between limonene and other EO phytochemicals (Costa et al., 2013). These
findings, combined with the results from this thesis, strongly imply that Limonene-
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CBD formulations are acting synergistically at the 5-HT1A receptor to exhibit their
anxiolytic effects within the LDB test.
In the last assay, the contextual fear conditioning (CFC) paradigm, there was
no significant reversal of the anxiolytic effect observed in the Limonene-CBD
formulations upon co-application of NAD299. This is in contrast to the findings by
Norris and colleagues (2016) demonstrating 5-HT1A-mediated anxiolysis by CBD
within the nucleus accumbens shell (NASh). Consequently, it appears that the
inhibition of fear-related memory consolidation by Limonene-CBD is mediated by a
unique mechanism.
One reason for these results could be due to the wide-spread effects of inhaled
limonene affecting structures such as, the basolateral amygdala, which has been
greatly implicated in the modulation of fear memory (Davis, 1992; Etkin et al., 2004;
Reznikov et al., 2018). Thus, it is possible that the localized administration of
NAD299 into the NASh is unable to effectively block the effects of limonene within
the BLA. Conversely, given that 5-HT2A signalling is associated with the formation of
fear memory (Clinard et al., 2015; Jiang et al., 2020), it is probable that 5-HT2A and
not 5-HT1A is modulating the anxiolytic effects in the CFC task.
4.3 5-HT1A-Mediated EE-Potentiated Anxiolytic Mechanism
While the investigation of the combinatorial effects of CBD and limonene is
unique to this thesis, previous literature has confirmed the 5-HT1A agonistic properties
of individual CBD and limonene administrations within these assays (Campos &
Guimarães, 2008; Costa et al., 2013; Fogaça et al., 2014; Norris et al., 2016;
Szkudlarek et al., 2019). Norris et al. (2016) demonstrated that microinfusions of
CBD into the nucleus accumbens shell (NASh) led to increased GABAergic activity
within the ventral tegmental area (VTA), which subsequently decreased VTA
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dopaminergic activity, with these effects being mediated by 5-HT1AR. Similarly,
limonene has been shown to increase GABA neurotransmission, and consequently
decrease dopamine levels within the nucleus accumbens (Yun, 2014; Zhou et al.,
2009). Although the method of limonene administration in the study by Yun (2014)
was intraperitoneal (i.p.), the transport of limonene to the brain is in fact, superior
when inhaled rather than injected i.p. (Satou et al., 2017), suggesting that similar
neurochemical effects are likely to be emulated within this study.
One possible mechanism of synergy is that sub-threshold doses of CBD and
limonene act concurrently at 5-HT1AR within the NASh either through allosteric
modulation or direct substrate-receptor complex effects to increase GABAergic
neurotransmission to the VTA, thereby decreasing DAergic activity to the NASh,
PFC, and hippocampus (Figure 3). Given that all subtypes of anxiety are related to
decreased GABA and 5-HT function, and subsequently enhanced DAergic activity
within the mesocorticolimbic system (Nikolaus et al., 2010), this mechanism would
explain the reduction in anxious phenotypes observed in the behavioural assays upon
Limonene-CBD co-application.
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4.4 Molecular Analysis: EE-Potentiated Anxiolysis is Mediated by MAPK and
PI3K-Akt Signal Transduction Pathways
Table 4: Summary of the Ratio of Phosphorylated:Total Protein Expression
from Western Blot Assays
Brain Region
Nucleus
Basolateral
Accumbens Shell Amygdala

Molecular
Biomarker

Prefrontal
Cortex

p/T-ERK 1

L2KCBD(5)
compared to VV and
VCBD(5)

----

----

L2KCBD(5)
compared to VV

----

L2KCBD(5)NAD
compared to VV
L2KCBD(5)
compared to VV and
VCBD(5)
p/T-ERK 2
L2KCBD(5)NAD
compared to VV and
VCBD(5)
---p/T-Akt Ser
473

---L2KCBD(5)
compared to VV

All CBD doses were 5 ng/0.5 μL, all volumes of limonene were 2000 μl, and the dose
of NAD299 was 100 ng/0.5 μL. “----" denotes no significant differences in treatment
groups “ ”, denotes significantly lower protein expression. One-Way ANOVA; p <
0.05.
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Based on the results from the behavioural assays demonstrating evidence of 5HT1A mediated synergistic anxiolysis between limonene and CBD, molecular analysis
of the highest combinatorial formulation of L2KCBD(5) was conducted alongside
VCBD(5) and L2KCBD(5)NAD. Expression levels of ERK1/2 of the MAPK pathway
and Akt of the PI3K-Akt pathway within the prefrontal cortex, nucleus accumbens
shell, and basolateral amygdala associated with the mesocorticolimbic system were
analyzed.
4.4.1 ERK1/2 Signalling Modulates Limonene-CBD Anxiolysis
Within the prefrontal cortex, the VCBD(5) group did not display significantly
lower levels of p/T-ERK1/2 expression (Figure 19C) relative to the VV group. This
outcome is consistent with data from Hudson et al. (2019) exhibiting no differences in
p/T-ERK1/2 levels between intra-hippocampus CBD (100 ng) and untreated subjects
and correlates with the lack of behavioural differences (relative to VV) observed in
this thesis in the assays from the Baseline Cohort. It should be noted, however, that
chronic administration of CBD (i.p. injection; 10.0 mg/kg) has been shown in
previous literature to decrease p-ERK1/2 (without affecting T-ERK1/2) within the
PFC and these effects have been linked to anxiogenic symptoms, as opposed to the
anxiolytic effects typically observed with acute administrations of CBD at the same
dose (ElBatsh et al., 2012). Notably, this discrepancy highlights the reported biphasic
therapeutic efficacy of orally and intraperitoneally delivered cannabidiol (Campos &
Guimarães, 2008, 2009; Guimarães et al., 1990).
For instance, Guimarães et al. (1990) observed that i.p. injections of 2.5, 5.0,
and 10.0 mg/kg significantly increased the open arm entry ratio in the elevated plus
maze, while 20.0 mg/kg was ineffective. Similar findings in the EPM task were
documented by Campos and Guimarães (2008) upon delivery of CBD into the
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dorsolateral periaqueductal gray midbrain structure. This bimodal activity has been
proposed to be due to the differential activation of receptors by cannabidiol, with
anxiolytic effects induced by 5-HT1AR activation at low doses (Campos &
Guimarães, 2008) and anxiogenic effects resulting from TRPV1 activation at high
doses and subsequent increase in glutamate transmission (Campos & Guimarães,
2009). Interestingly, this bell-shaped response curve appears to be overcome by CBD
extracts enriched with other components, with increasing doses corresponding to
increasingly more effective anti‐inflammatory and anti‐nociceptive effects (Gallily et
al., 2015). Consequently, Gallily and colleagues (2015) have proposed that potential
synergistic effects between various phytocannabinoids may make combinatorial
extracts more clinically effective than isolated CBD, thereby, providing additional
support for the proposition that combining CBD and limonene may result in greater
anxiolytic efficacy than increasing doses of CBD alone.
p/T-ERK1/2 levels were significantly reduced in the PFC in the L2KCBD(5)
group relative to the VV and VCBD(5) groups (Table 4; Figure 19C) suggesting that
limonene is likely reinforcing the effects of sub-threshold CBD in decreasing
phosphorylated ERK1/2 levels. Given that phosphorylated ERK within the PFC is
linked to high levels of anxiety (Ailing et al., 2008), these results correlate with
outcomes from our behavioural assays (namely, the elevated plus maze and light dark
box) in the Baseline Cohort in which the L2KV group displayed greater anxiolysis
relative to the VV group, and wherein Limonene-CBD groups exhibited the greatest
anxiolytic efficacy.
Potential mechanisms by which limonene may synergize the anxiolytic effects
of CBD within the MAPK pathway include i) interactions at 5-HT1AR via allosteric or
direct receptor complexes, ii) alteration of molecular targets upstream of ERK1/2
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(such as, Ras, Raf, and MEK1-2), iii) alteration of downstream nuclear localization
effectors such as, cAMP-response-element-binding protein (CREB), iv) modulation
of proteins and other associated pathways outside the scope of this thesis, and iv) a
combination of these effects (Figure 21).
While there are currently no studies on the influence of d-limonene on MAPK
proteins as it relates to anxiety, the assertion that limonene affects the MAPK
pathway is supported by in-vivo and in-vitro data examining other disease conditions.
Essential oils from the citrus plant (composed of 52.44% limonene) have been found
to decrease the levels of phosphorylated MAPKs (JNK and ERK) in-vitro resulting in
anti-inflammatory effects (Kim et al., 2013), while Younis (2020) revealed that
limonene pre-treatment reduced the expression of MAPK proteins and p/T-ERK
levels in rats experiencing myocardial injury. Moreover, Chaudhary et al. (2012)
demonstrated that limonene decreased the expression of Ras, Raf, and phosphorylated
ERK1/2 levels in a mouse model of skin tumorigenesis supporting the proposition
that the reduction in p-ERK1/2 levels observed in this thesis may be a result of Ras or
Raf inactivation upstream of ERK1/2.
In contrast, the anxiolytic behavioural effects of Limonene-CBD could be a
result of direct inactivation of ERK1/2 affecting downstream target effectors such as
CREB, and subsequent changes in mRNA production (Figure 4). Within the
hippocampus, the 5-HT1A-mediated induction of CREB by activated ERK1/2 is
associated with the modulation of anxiety behaviours (Zhang et al., 2016), while drug
or stress-induced activation of CREB within the NAc or amygdala results in
depressive and anxiety-like behaviors (Carlezonjr et al., 2005; Pandey et al.,
2003). Therefore, a long-term consequence of Limonene-CBD administration may be
a decrease in the phosphorylation and consequently, the inactivation of PFC-ERK1/2,
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thereby, leading to reduced CREB activity and anxiety. That said, within the context
of this thesis, the assertion that these formulations are inducing long-term changes
through nuclear localization of downstream effectors should be made with caution, as
drug administrations in this study were acute, or at most sub-chronic, in nature. Thus,
anxiolysis via rapid-acting, short-term changes are important to consider.
One possible immediate alteration is the formation of stress-induced free
radicals and reactive oxygen species (ROS) that are implicated in the prognosis and
maintenance of neurogenerative disease. In rats, conditions of acute (1 hour) (Nadeem
et al., 2006) and chronic stress (21 days) (Zafir & Banu, 2009) result in the formation
of reactive oxygen species, with increased ROS resulting in the phosphorylation and
activation of ERK (Cao & Kaufman, 2014). Intracellular accumulation of ROS within
the cerebral cortex, cerebellum, and hippocampus has been linked to anxious
phenotypes in mice (Rammal et al., 2008) with increased intracellular ROS positively
correlating with measures of anxiety in the light-dark box (Bouayed et al., 2007).
Given the acute/sub-chronic quality of the stress assumed by the subjects in this
thesis, the notion that high ROS levels are mediating anxious behaviour is not
unlikely. Accordingly, the decreased p/T-ERK levels observed in the Limonene-CBD
group could arguably be a consequence of the 5-HT1A-mediated reduction in ROS
activity, given the in-vitro evidence demonstrating the antioxidant properties (via the
inhibition of ROS) of both cannabidiol and limonene (Campos et al., 2016;
Mechoulam et al., 2007; Shah & Mehta, 2018)
In addition to revealing changes in downstream effectors, a principal objective
of this thesis was to elucidate the chief receptor targeted by the Limonene-CBD
formulations. As expected from the NAD299 Challenge behavioural assays (namely,
EPM and LDB) illustrating reversal of anxiety-related behaviour upon administration
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of NAD299, the L2KCBD(5)NAD group displayed higher levels of p/T-ERK1/2 than
the L2KCBD(5) group (Figure 19C), suggesting that the Limonene-CBD mediation
of ERK is occurring at the 5-HT1A receptor. That said, the possibility that limonene is
modulating these effects by interactions with other receptor targets should not be
excluded.
For instance, the antioxidant properties of limonene have been linked to its
modulation of 5-HT2A signalling (Yun, 2014) and 5-HT2AR activation is associated
with the potent inhibition of the tumor necrosis factor-alpha (TNF-α) (Nau et al.,
2013). Moreover, citrus essential oils containing a high concentration of limonene
have been found to dose-dependently suppress TNF-α (Kim et al., 2013), while
administration of cannabidiol reduces serum TNF-α expression in a biphasic manner
(Gallily et al., 2015). These findings are noteworthy as blocking TNF-α reduces
anxiety and depressive-like behaviors (Alshammari et al., 2020). Given that TNF-α
phosphorylates and activates ERK proteins (Sabio & Davis, 2014), the reduction in pERK1/2 expression observed in the Limonene-CBD group could allude to potential
inhibition of TNF-α activity. Collectively then, these findings suggest that limonene
and/or CBD inhibits TNF-α signalling via 5-HT2AR, leading to decreased p/T-ERK1/2
expression and a reduction in anxious phenotypes. Conversely, an alternative
mechanism pertains to the downregulation of p-ERK1/2 (by limonene) resulting in
decreased 5-HT2AR expression as expected from data by Xiang et al. (2017) reporting
these effects. Given that 5-HT2AR expression competitively inhibits 5-HT1AR in the
hippocampi of PTSD mice (Xiang et al., 2017), this reduction in 5-HT2AR could
facilitate the therapeutic effects of 5-HT1A-mediated anxiolysis by CBD. Regardless
of which mechanism of action underlies the observed 5-HT1AR associated anxiolysis,
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the prospect of additional targets aiding in this process should be examined by the use
of respective receptor antagonists.
According to findings from this thesis, ERK levels appear to be modulated
specifically within the PFC as indicated by the lack of significant differences in p/TERK levels observed within the BLA and NASh (aside from the significant reduction
in NASh p/T-ERK2). Given that drug delivery did not include intra-PFC
administration, these results highlight the functional connections between the PFC
and NASh, specifically NASh-mediated inhibition of PFC-MAPK/ERK signalling
and the PFC-mediated GABAergic and glutamatergic input to the NASh; thus, some
contributory effects via GABA or glutamate neurotransmission are likely modulating
the observed EE-potentiated anxiolysis. Specifically, synaptic GABA release in
neurons has been found to lower levels of p-ERK, while the inhibition of MEK1/2 (an
upstream activator of ERK) reduces p-ERK and increases GABAAR peak current
amplitudes (Brady et al., 2018). Therefore, at the systems level, intra-NASh drug
delivery may modulate PFC neurotransmission indirectly (via associations with the
VTA), and the consequent increase in PFC GABAergic neurotransmission to the
NASh decreases PFC-p-ERK1/2 and anxious behaviour.
In summary, the reduction in p/T-ERK1/2 expression observed in the
Limonene-CBD group offer a few 5-HT1A-mediated mechanisms that may underlie
the EE-potentiated anxiolysis established in the behavioural assays including, joint
reduction in ROS activity, modulation of GABAergic transmission, long-term
alterations in CREB activity, or a combination of these effects. Moreover, interactions
with other receptors such as the 5-HT2AR-mediated reduction in TNF-α or
competitive inhibition of 5-HT1AR, are necessary to consider given the reported
diversity in the properties associated with CBD and limonene. The lack of anxiolytic
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behavioural efficacy detected by administrations of isolated CBD and often, in
isolated limonene doses, together with the fact that CBD alone did not significantly
alter ERK1/2 expression, underscore a unique mechanism of action that likely
modulates the synergistic efficacy of combinatorial limonene and CBD via the MAPK
pathway.

.
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4.4.2 Akt Signalling Modulates Limonene-CBD Anxiolysis
Data by Renard et al. (2016) utilizing a higher dose of CBD (100 ng) and the
same intra-NASh delivery method employed in this thesis found significantly
decreased levels of p-Akt Ser473 and p/T-Akt Ser 473 in CBD-treated rats. It should
be noted that while these findings by Renard et al. (2016) were reported in AMPHsensitized rats and thus, may not represent an ideal model of comparison, similar
trends have been documented in CBD-treated glioblastoma cells by Ivanov et al.
(2017). Conversely, the VCBD(5) group of this study did not display a significant
reduction in this biomarker in any of the brain regions analyzed (Figure 20)
correlating with the absence of anxiolysis observed in the behavioural assays.
Together, these findings support the assertion that 5 ng of CBD is a sub-threshold
dose and that the observed L2KCBD(5) reduction of p/T-Akt Ser 473 in the NASh
and the associated reduction in anxiety-related behaviour is a consequence of
limonene modulation.
Although yet to be examined in mood and anxiety-related states, limonene
inhibition of p-Akt Ser 473 has been well-established in human cancer cells
(Chidambara Murthy et al., 2012; Jia et al., 2013; Reddy et al., 2017). Moreover, the
contention that limonene may synergize the effects of CBD is corroborated by data
from Saunders et al. (2014) revealing that KO mice with ablated Akt phosphorylation
at Ser473 display increased 5-HT1AR binding and wherein, in-vitro pharmacological
inhibition of Akt subsequently enhances 5-HT1AR cortical expression. Collectively,
these findings offer a mechanism of interaction whereby, limonene reduction in p-Akt
could potentially increase the available 5-HT1A receptor pool for CBD to exert its
anxiolytic effects. Moreover, the observed trend in increased NASh-p/T-Akt Ser 473
in the L2KCBD(5)NAD group (Figure 20F) correlating with the reversal to anxious
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behaviour observed in the NAD299 Challenge Cohort support this proposition of 5HT1AR mediated synergy.
Although not analyzed in this thesis, the study by Renard and colleagues
(2016) mentioned previously revealed that in addition to p-Akt downregulation, CBD
concurrently inhibited the expression of GSK3β (a downstream target of Akt), which
is in contrast to the reported effects of traditional antipsychotics that exhibit a
reciprocal increase in GSK3β upon Akt inactivation (Beaulieu et al., 2009).
Accordingly, Renard et al. (2016) have proposed that a novel molecular pathway
likely underlies the therapeutic effects of CBD within the mesolimbic system which
bypasses the conventional PI3K-Akt-GSK3 pathway of conventional antipsychotics.
Given the assertion that limonene is a key player modulating the anxiolytic
properties of these formulations, it is worthwhile understanding how olfactory
nervous system activation by limonene can lead to alterations at the molecular level.
The presence of limonene in the brain after 30-minute inhalation has been
documented by Satou et al. (2017), and when combined with the fact that chemical
compounds activate the olfactory bulb neurons which transmit signals to the olfactory
cortex, as well as the amygdala, hypothalamus, and hippocampus involved in
emotion, hormone secretion, and memory, respectively (Koyama & Heinbockel,
2020), alterations in behaviour are a plausible consequence of odourous limonene.
That said, electrophysiological recordings analyzing changes in activity within
specific brain regions following limonene inhalation would aid in extending the work
of this thesis beyond the speculated correlations made between biomarker expression,
neurotransmission, and behavioural phenomena.
Taken together, the MAPK and PI3/Akt molecular changes observed within
the PFC and NASh, respectively, offer two different 5-HT1A-associated mechanistic
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pathways that are altered by these Limonene-CBD formulations. Importantly,
although this data highlights the circuit-level connections between the brain regions of
the MCL system (namely, the NASh and PFC), the exact manner in which these
regions communicate with each other to evoke these changes remains unclear.
Moreover, given the reciprocal interactions between the NASh and VTA and the
indirect modulation of the PFC via this connection, further investigations involving
functional disconnection between these brain regions (alongside the application of
specific inhibitors) would aid in clarifying the observed EE-potentiated anxiolytic
mechanism of Limonene-CBD. Finally, the examination of supplementary pathways
such as the ADCY/cAMP/PKA cascade, and additional biomarkers such as JNK and
GSK3, would better inform the conclusion that Limonene and CBD regulate anxiety
via the 5-HT1A receptor.

Figure 21: Schematic of Potential Proteins Targeted by Limonene and CBD in
Modulating Anxiety (as presented in Discussion).
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5. Conclusions and Future Directions
Changes in the legal landscape surrounding recreational and non-prescriptive
cannabis practices have prompted scientific investigation to better inform safe and
responsible usage. Moreover, advances in pre-clinical and clinical research
elucidating the divergent effects of different phytocannabinoids (i.e., CBD and THC)
and the remedial properties of terpenes, have highlighted the therapeutic potential of
cannabis-derived components. In particular, the discovery that combinatorial
formulations of different phytocannabinoids are more effective than isolated
administrations, termed the Entourage Effect, have provoked scientific inquiry on
whether specific phytocannabinoid-terpene combinations could elicit greater
therapeutic efficacy. Given the documented anxiolytic properties of individual
administrations of the monoterpene d-limonene and the phytocannabinoid
cannabidiol, this thesis explored the presence of potential Entourage Effectpotentiated anxiolysis in combinatorial doses of Limonene-CBD.
Utilizing a rodent model of open-space and bright-space anxiety, and fearrelated memory formation, this study demonstrated for the first time the synergistic
and consequently, enhanced anxiolytic efficacy of concurrently inhaled limonene
(200 μL or 2000 μL) and intra-nucleus accumbens shell cannabidiol (1 ng/0.5 μL or 5
ng/0.5 μL) in conditions of acute stress, as well as the absence of anxiolysis in a
model of social anxiety; dose-dependent effects could not be conclusively determined,
however, given that combinations of the lowest dose of each component (200 μL of
limonene + 1 ng/0.5 μL or 5 ng/0.5 μL of CBD) evoked similar anxiolysis compared
to the highest dose combination treatment (2000 μL of limonene + 5 ng/0.5μL of
CBD).
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Moreover, correlations between behavioural outcomes and the detected
changes in the L2KCBD(5) group in ERK1/2 expression within the PFC and Akt
Ser473 within the NASh (relative to CBD alone), not only substantiated the
facilitative effects of limonene in synergizing the anxiolytic effects of CBD but also
highlighted the functional connections between the associated brain regions of the
mesocorticolimbic system in this regulation. Although questions remain on precisely
how intra-NASh delivery is communicating with the PFC and VTA and whether
various receptor targets may be aiding in the synergistic anxiolysis of Limonene-CBD
dosages, outcomes from this thesis support the well-established role of the NASh, and
specifically CBD within the NASh, in regulating affective processing, thereby,
emphasizing this brain region as a useful target in treating mood and anxiety
disorders. Furthermore, delivery of these formulations with co-applied NAD299
hydrochloride and the consequent reversal of behavioural effects and related
biomarker activity validated the role of 5-HT1AR in mediating Limonene-CBD
synergistic anxiolysis.
While further work involving functional disconnection and
electrophysiological analysis would aid in clarifying the mechanisms presented in this
thesis, data obtained from this investigation adds to the growing body of knowledge
on the Entourage Effect observed amongst cannabis-derived phytochemicals.
Moreover, given the enhanced pharmacological safety and relative lack of adverse
side-effects associated with limonene and CBD when compared to conventional antianxiety medications, this study opens up a potential avenue to consider in terms of
naturally-derived anxiolytics that may aid or substitute current pharmacotherapies.
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